健心汤对心力衰竭的疗效观察及抗心肌重塑机制研究
|
摘要
慢性心力衰竭为临床常见病及多发病,是各种心脏病发展至晚期的结局,手术和介入治疗的适应症很少,最主要的仍是药物治疗。尽管ACEI和β受体阻滞剂的应用,改善了心衰患者的运动耐量和生活质量,然而其预后仍然非常差,年死亡率高达10%-50%,所以开展药物治疗慢性心力衰竭方面的研究具有重要意义。
应用中医药治疗心力衰竭是祖国医学的一大特色,临床报道并非少见,但系统的临床与实验研究尚不多见,有关中医药治疗心力衰竭的作用机制研究仍不够深入。健心汤是我院心内科治疗慢性心力衰竭的经验方,已在临床上应用并证实有效,但其治疗心力衰竭的机制尚不十分清楚,仍有待进一步探讨。因此,本研究从临床和基础两方面探讨健心汤的抗心衰作用及其可能机制,为心力衰竭的防治和健心汤的进一步临床应用奠定基础。
第一部分临床研究
目的:观察健心汤治疗慢性心力衰竭的临床疗效及安全性,并初步探讨其作用机制。
方法:选取NYHA心功能分级Ⅱ-Ⅲ级的心力衰竭患者50例,随机分为对照组(25例)和治疗组(25例)。对照组给予常规西药治疗,治疗组在常规西药治疗基础上加用健心汤治疗6周。观察患者用药期间心功能的改善及安全性、不良反应,评估健心汤对心衰患者运动耐量和生活质量的影响,ELISA法检测治疗前后NT-proBNP和和肽素(Copeptin)的水平。
结果:1.对照组和治疗组均可改善心力衰竭患者心功能,对照组总有效率80%,治疗组92%,两组总疗效比较有显著性差异(P＜0.05)。
2.治疗后两组的NYHA分级和Lee氏心衰计分均较治疗前降低(P＜0.05),治疗组比对照组降低更明显(P＜0.05)。
3.两组患者治疗前后超声各参数比较:LVEF、FS较治疗前升高(P＜0.05),LVESV较治疗前降低(P＜0.05);治疗组LVEDV较治疗前降低(P＜0.05)。
治疗后两组间比较:LVEF、FS较对照组升高(P＜0.05),LVESV较对照组降低(P＜0.05)。
4.治疗后两组的6分钟步行距离较治疗前延长(P＜0.05),且两组间比较有显著性差异(P＜0.05),治疗组6分钟步行距离更长。
5.治疗后两组NT-proBNP和Copeptin水平均较治疗前降低(P＜0.05),治疗组降低更明显(P＜0.05)。
6.治疗后两组明尼苏达心衰生活质量积分均较治疗前降低(P＜0.05),治疗组降低更明显(P＜0.05)。
7.治疗组和对照组均未发生明显的肝肾损害等不良反应。
结论:1.在常规西药治疗的基础上,健心汤能够进一步增强疗效、改善心功能、提高心衰患者的运动耐量和生活质量,与常规西药治疗有协同作用。
2.健心汤可降低心衰患者NT-proBNP和Copeptin的水平,提示健心汤是治疗慢性心衰的有效制剂。
3.健心汤治疗慢性心衰6周内无明显毒副作用,安全性较好。
第二部分基础研究
目的:观察健心汤对心功能及左室重构的影响,并探讨其可能机制,为临床治疗心衰提供理论依据。
方法:结扎SD大鼠冠状动脉前降支建立心梗后心衰模型,将76只心衰大鼠随机分成4组:健心汤低剂量组(低剂量组),健心汤高剂量组(高剂量组),培垛普利组,心衰对照组;另取15只大鼠只穿线不结扎冠状动脉前降支为假手术组。分别给予健心汤7.65g/kg和15.30g/kg、雅施达0.72mg/kg灌胃治疗共6周。假手术组、心衰对照组灌服等剂量纯净水。6周后观察:(1)大鼠一般情况、死亡率、体重、全心重量指数(THMI)和左室重量指数(LVMI)变化;(2)超声心功能参数;(3)心肌组织HE染色;(4)Masson染色法观察胶原含量,并计算胶原容积份数(CVF);免疫组化法测定心肌组织Ⅰ型和Ⅲ型胶原水平;(5)放免法检测心肌组织AngⅡ、ET水平,ELISA法检测血浆NT-proBNP水平;RT-PCR法检测心肌组织ET、NT-proBNP mRNA的表达;(6)Western Blot法测定心肌组织p-ERK_(1/2)、p38-MAPK蛋白的表达。
结果:1.健心汤治疗后,心衰大鼠的死亡率降低,体重增长,THMI和LVMI降低(P均＜0.05),但低剂量组、高剂量组、培垛普利组间比较无显著性差异(P＞0.05)。
2.健心汤治疗后,心衰大鼠的LVEDD降低、FS和LVEF升高(P均＜0.05),且FS和LVEF在高剂量组与培垛普利组升高较低剂量组更明显(P＜0.05):
3.健心汤可改善心衰大鼠病理形态结构,高剂量组和培垛普利组较低剂量组更佳。
4.健心汤治疗后,心衰大鼠的Ⅰ型胶原含量、Ⅰ/Ⅲ型胶原比值、CVF降低(P＜0.05),且在高剂量组与培垛普利组较低剂量组降低更明显(P＜0.05)。
5.健心汤治疗后,心衰大鼠AngⅡ、ET和NT-proBNP水平均降低(P均＜0.05),但培垛普利组AngⅡ水平较低剂量组和高剂量组更低(P＜0.05);ET和NT-proBNP水平在高剂量组和培垛普利组无显著性差异(P＞0.05),均低于低剂量组(P＜0.05)。
6.健心汤治疗后,p-ERK_(1/2)、p38-MAPK蛋白水平较心衰对照组降低(P＜0.05),且在高剂量组与培垛普利组较低剂量组降低更明显(P＜0.05)。
结论:1.健心汤可改善心衰大鼠的心功能、心肌形态结构,是治疗心衰的有效制剂。
2.健心汤降低了心衰大鼠Ⅰ型胶原、Ⅰ/Ⅲ胶原比值、CVF水平,提示健心汤可能通过调节胶原的表达抗心肌重塑。
3.健心汤降低了心衰大鼠AngⅡ、ET、NT-proBNP水平,提示健心汤可以拮抗心衰大鼠神经内分泌系统的过度激活。
4.健心汤下调了心衰大鼠p-ERK_(1/2)、p38-MAPK蛋白表达水平,提示健心汤可能通过干预了细胞信号转导系统的ERK、p38通路,通过相关的级联信号分子达到抗心肌重塑的作用。
5.高剂量健心汤对心功能的改善和抗心肌重塑的作用在6周内与培垛普利大致相当。
Congestive heart failure (CHF) is a common disease, and has become one of the most important public sanitary problems. CHF is the end-stage of various heart diseases. Operation and invention treatment are not widely used, and the major one is still drug treatment. Although the application of ACEI andβ-blocker could improve the life quality and exercise tolerance of patients with heart failure, the prognosis is so poor that the mortality is as high as 10 to 50 percent.
The treatment with traditional Chinese medicine for congestive heart failure is a major feature of traditional Chinese medicine. Clinic reports are not unusual, but systemic reports on both clinic and laboratory are not yet common. The Study that is associated with the treatment with traditional Chinese medicine for congestive heart failure is lack of depth. Jian Xin Soup has been used in clinic and be testified effectively to treat heart failure. However, the exact mechanism of anti-heart failure treatment is not yet known and need to be explored further. The possible mechanism of Jian Xin Soup curing congestive heart failure from both clinical and experimental sides will be explored in further study.
Part 1: Clinical Research
Objective: To investigate the effect and safety of Jian Xin Soup on CHF and to study its probable mechanism.
Methods: 50 Patients with CHF and NYHA grade II-III were studied, and randomly divided into the treatment group (n=25) and control group (n=25). The control group was treated with conventional western medicine, while the treatment group was treated with Jian Xin Soup twice a day for 6 weeks as well as western medicine. Side-effects and heart function were recorded during drug administration. 6 minute walk test (6MWT) and Minnesota living with heart failure questionnaire (MLHFQ) were also used to estimate exercise performance and life quality. The level of plasma NT-proBNP and Copeptin was investigated by ELISA assay.
Results: 1. The total effective rate in treatment group was 92%, while in control group was 80%, there was significant difference between the two groups (P<0.05) .
2. Lee's marks of CHF and NYHA classification was decreased significantly in both groups after treatment (P<0.05) ,and with even better decrease in treatment group than that in control group (P<0.05) .
3. The LVEF, LVESV and FS was improved significantly in both groups after treatment (P< 0.05),but the improvement in treatment group was more significant than that in control group (P<0.05) . After treatment, there was significant difference in treatment group with LVEDV than that before treatment (P<0.05) , but with no significant difference in control group (P>0.05) .
4. After treatment, the distance of 6MWT was increased signifieantly in both groups (P<0.05) ,and with even better increase in treatment group than that in control group (P<0.05) .
5. After treatment, the concentration of NT-proBNP and Copeptin was decreased significantly in both groups (P<0.05) ,and with even better decrease in treatment group than that in control group (P<0.05) .
6. After treatment, the marks of MLHFQ was decreased significantly in both groups (P<0.05) ,and with even better decrease in treatment group than that in control group (P<0.05) .
7. No side-effects such as the liver and kidney function damage were recorded in both groups.
Conclusions: 1. Jian Xin Soup could strengthen the therapeutic effects, improve heart function, enhance exercise performance and life quality, and it has cooperative function with conventional western medicine on CHF treatment.
2. Jian Xin Soup could decrease the level of NT-proBNP and Copeptin, and it may suggest that Jian Xin Soup is effective in the treatment of CHF.
3. Jian Xin Soup has no side effects, and it is very safe in six weeks.
Objective: To investigate the effects of Jian Xin Soup on heart function and left ventricular remodeling in order to find some possible mechanism and provide evidence to clinical application.
Methods: 76 model rats with CHF were randomly divided into 4 groups, that is, Jian Xin Soup low dose group, Jian Xin Soup high dose group, HF control group, and Perindopril group, 19 in each group. Another 15 rats are the sham operation group. In Jian Xin Soup low dose group, each rat is fed with 7.65g/kg; in Jian Xin Soup high dose group with Jian Xin Soup 15.30g/kg, and in Perindopril group with Perindopril 0.72mg/kg, Sham operation group and the control group is fed with 1ml/kg water. All rats were fed twice a day for 6 weeks. The measurement included: (1) mortality, body weight, total heart mass indexes(THMI),and left ventricular mass indexes(LVMI) were observed; (2) before and after the treatment, the IVST, LVPWT, LVEDD, FS, LVEF were recorded by Echocardiography; (3) pathologic changes of left ventricular myocardium were viewed with HE staining method; (4) collagen volume fraction (CVF) was done with patho-image analytical system; Expression of collagen type I and III was measured by immuno-hisochemical method, and the ratio of collagen type I and III was calculated; (5) concentration of AngII and ET in left ventricular myocardium was measured by radio-immunity method, the level of plasma NT-proBNP was measured by ELISA assay. The levels of ET and NT-proBNP mRNA in left ventricular myocardium were measured by RT-PCR; (6) the expression of p-ERK_(1/2) and p38-MAPK in left ventricular myocardium was measured by Western blot.
Results: 1. After the medication treatment, the mortality, THMI and LVMI were significantly decreased in those of all treatment groups (P< 0.05) , but there was no obvious difference among the treatment groups (P>0.05) .
2. Compared to sham operated group, in HF control group LVEDD was obviously increased and FS LVEF was decreased (P<0.05) ; After treatment, heart function improved compared to that of HF control group(P<0.05) , FS and LVEF were better in Jian Xin Soup high dose group and Perindopril group than those in Jian Xin Soup low dose group.
3. After the treatment of Jian Xin Soup, the pathomorphology of myocardium had been improved with dose-dependence, they were better in Jian Xin Soup high dose group and Perindopril group than those in Jian Xin Soup low dose group, but there was no obvious difference between Jian Xin Soup high dose group and Perindopril group.
4. After the medication treatment, the levels of type I collagen, ratio of collagen type I and III and CVF were significantly decreased in all treatment groups (P<0.05), lower in Jian Xin Soup high dose group and Perindopril group than that in Jian Xin Soup low dose group.
5. After the medication treatment, the level of AngII, ET and NT-proBNP were significantly decreased in all treatment groups (P< 0.05), but the level of AngII was the lowest in Perindopril group compare to that in the other two groups (P<0.05) . The levels of ET and NT-proBNP were lower in Jian Xin Soup high dose group and Perindopril group than those in Jian Xin Soup low dose group, but there was no obvious difference between Jian Xin Soup high dose group and Perindopril group (P>0.05) .
6. After the medication treatment, the levels of p-ERK_(1/2) and p38-MAPK were significantly decreased in all treatment groups (P< 0.05) , but the levels of p-ERK_(1/2) and p38-MAPK were lower in Jian Xin Soup high dose group and Perindopril group than those in Jian Xin Soup low dose group, but there was no obvious difference between Jian Xin Soup high dose group and Perindopril group (P>0.05) .
Conclusions: 1. Jian Xin Soup may be effective in the treatment of CHF through improving the CHF rats' heart function and tissue morphology.
2. Jian Xin Soup could decrease the level of type I collagen, ratio of collagen type I and III and CVF, it may regress ventricular remodeling through reversing collagen remodeling.
3. Jian Xin Soup could decrease the level of AngII, ET and NT-proBNP, it may regress ventricular remodeling through restraining over-excitation of nerve endocrine system.
4. Jian Xin Soup could decrease the level of p-ERK_(1/2) and p38-MAPK, it may regress ventricular remodeling through regulating the abnormal signal pathway of ERK and p38.
5. Jian Xin Soup could improve heart function and regress ventricular remodeling. There was no obvious difference in therapeutic effects between Jian Xin Soup and Perindopril in six weeks.
应用中医药治疗心力衰竭是祖国医学的一大特色,临床报道并非少见,但系统的临床与实验研究尚不多见,有关中医药治疗心力衰竭的作用机制研究仍不够深入。健心汤是我院心内科治疗慢性心力衰竭的经验方,已在临床上应用并证实有效,但其治疗心力衰竭的机制尚不十分清楚,仍有待进一步探讨。因此,本研究从临床和基础两方面探讨健心汤的抗心衰作用及其可能机制,为心力衰竭的防治和健心汤的进一步临床应用奠定基础。
第一部分临床研究
目的:观察健心汤治疗慢性心力衰竭的临床疗效及安全性,并初步探讨其作用机制。
方法:选取NYHA心功能分级Ⅱ-Ⅲ级的心力衰竭患者50例,随机分为对照组(25例)和治疗组(25例)。对照组给予常规西药治疗,治疗组在常规西药治疗基础上加用健心汤治疗6周。观察患者用药期间心功能的改善及安全性、不良反应,评估健心汤对心衰患者运动耐量和生活质量的影响,ELISA法检测治疗前后NT-proBNP和和肽素(Copeptin)的水平。
结果:1.对照组和治疗组均可改善心力衰竭患者心功能,对照组总有效率80%,治疗组92%,两组总疗效比较有显著性差异(P＜0.05)。
2.治疗后两组的NYHA分级和Lee氏心衰计分均较治疗前降低(P＜0.05),治疗组比对照组降低更明显(P＜0.05)。
3.两组患者治疗前后超声各参数比较:LVEF、FS较治疗前升高(P＜0.05),LVESV较治疗前降低(P＜0.05);治疗组LVEDV较治疗前降低(P＜0.05)。
治疗后两组间比较:LVEF、FS较对照组升高(P＜0.05),LVESV较对照组降低(P＜0.05)。
4.治疗后两组的6分钟步行距离较治疗前延长(P＜0.05),且两组间比较有显著性差异(P＜0.05),治疗组6分钟步行距离更长。
5.治疗后两组NT-proBNP和Copeptin水平均较治疗前降低(P＜0.05),治疗组降低更明显(P＜0.05)。
6.治疗后两组明尼苏达心衰生活质量积分均较治疗前降低(P＜0.05),治疗组降低更明显(P＜0.05)。
7.治疗组和对照组均未发生明显的肝肾损害等不良反应。
结论:1.在常规西药治疗的基础上,健心汤能够进一步增强疗效、改善心功能、提高心衰患者的运动耐量和生活质量,与常规西药治疗有协同作用。
2.健心汤可降低心衰患者NT-proBNP和Copeptin的水平,提示健心汤是治疗慢性心衰的有效制剂。
3.健心汤治疗慢性心衰6周内无明显毒副作用,安全性较好。
第二部分基础研究
目的:观察健心汤对心功能及左室重构的影响,并探讨其可能机制,为临床治疗心衰提供理论依据。
方法:结扎SD大鼠冠状动脉前降支建立心梗后心衰模型,将76只心衰大鼠随机分成4组:健心汤低剂量组(低剂量组),健心汤高剂量组(高剂量组),培垛普利组,心衰对照组;另取15只大鼠只穿线不结扎冠状动脉前降支为假手术组。分别给予健心汤7.65g/kg和15.30g/kg、雅施达0.72mg/kg灌胃治疗共6周。假手术组、心衰对照组灌服等剂量纯净水。6周后观察:(1)大鼠一般情况、死亡率、体重、全心重量指数(THMI)和左室重量指数(LVMI)变化;(2)超声心功能参数;(3)心肌组织HE染色;(4)Masson染色法观察胶原含量,并计算胶原容积份数(CVF);免疫组化法测定心肌组织Ⅰ型和Ⅲ型胶原水平;(5)放免法检测心肌组织AngⅡ、ET水平,ELISA法检测血浆NT-proBNP水平;RT-PCR法检测心肌组织ET、NT-proBNP mRNA的表达;(6)Western Blot法测定心肌组织p-ERK_(1/2)、p38-MAPK蛋白的表达。
结果:1.健心汤治疗后,心衰大鼠的死亡率降低,体重增长,THMI和LVMI降低(P均＜0.05),但低剂量组、高剂量组、培垛普利组间比较无显著性差异(P＞0.05)。
2.健心汤治疗后,心衰大鼠的LVEDD降低、FS和LVEF升高(P均＜0.05),且FS和LVEF在高剂量组与培垛普利组升高较低剂量组更明显(P＜0.05):
3.健心汤可改善心衰大鼠病理形态结构,高剂量组和培垛普利组较低剂量组更佳。
4.健心汤治疗后,心衰大鼠的Ⅰ型胶原含量、Ⅰ/Ⅲ型胶原比值、CVF降低(P＜0.05),且在高剂量组与培垛普利组较低剂量组降低更明显(P＜0.05)。
5.健心汤治疗后,心衰大鼠AngⅡ、ET和NT-proBNP水平均降低(P均＜0.05),但培垛普利组AngⅡ水平较低剂量组和高剂量组更低(P＜0.05);ET和NT-proBNP水平在高剂量组和培垛普利组无显著性差异(P＞0.05),均低于低剂量组(P＜0.05)。
6.健心汤治疗后,p-ERK_(1/2)、p38-MAPK蛋白水平较心衰对照组降低(P＜0.05),且在高剂量组与培垛普利组较低剂量组降低更明显(P＜0.05)。
结论:1.健心汤可改善心衰大鼠的心功能、心肌形态结构,是治疗心衰的有效制剂。
2.健心汤降低了心衰大鼠Ⅰ型胶原、Ⅰ/Ⅲ胶原比值、CVF水平,提示健心汤可能通过调节胶原的表达抗心肌重塑。
3.健心汤降低了心衰大鼠AngⅡ、ET、NT-proBNP水平,提示健心汤可以拮抗心衰大鼠神经内分泌系统的过度激活。
4.健心汤下调了心衰大鼠p-ERK_(1/2)、p38-MAPK蛋白表达水平,提示健心汤可能通过干预了细胞信号转导系统的ERK、p38通路,通过相关的级联信号分子达到抗心肌重塑的作用。
5.高剂量健心汤对心功能的改善和抗心肌重塑的作用在6周内与培垛普利大致相当。
Congestive heart failure (CHF) is a common disease, and has become one of the most important public sanitary problems. CHF is the end-stage of various heart diseases. Operation and invention treatment are not widely used, and the major one is still drug treatment. Although the application of ACEI andβ-blocker could improve the life quality and exercise tolerance of patients with heart failure, the prognosis is so poor that the mortality is as high as 10 to 50 percent.
The treatment with traditional Chinese medicine for congestive heart failure is a major feature of traditional Chinese medicine. Clinic reports are not unusual, but systemic reports on both clinic and laboratory are not yet common. The Study that is associated with the treatment with traditional Chinese medicine for congestive heart failure is lack of depth. Jian Xin Soup has been used in clinic and be testified effectively to treat heart failure. However, the exact mechanism of anti-heart failure treatment is not yet known and need to be explored further. The possible mechanism of Jian Xin Soup curing congestive heart failure from both clinical and experimental sides will be explored in further study.
Part 1: Clinical Research
Objective: To investigate the effect and safety of Jian Xin Soup on CHF and to study its probable mechanism.
Methods: 50 Patients with CHF and NYHA grade II-III were studied, and randomly divided into the treatment group (n=25) and control group (n=25). The control group was treated with conventional western medicine, while the treatment group was treated with Jian Xin Soup twice a day for 6 weeks as well as western medicine. Side-effects and heart function were recorded during drug administration. 6 minute walk test (6MWT) and Minnesota living with heart failure questionnaire (MLHFQ) were also used to estimate exercise performance and life quality. The level of plasma NT-proBNP and Copeptin was investigated by ELISA assay.
Results: 1. The total effective rate in treatment group was 92%, while in control group was 80%, there was significant difference between the two groups (P<0.05) .
2. Lee's marks of CHF and NYHA classification was decreased significantly in both groups after treatment (P<0.05) ,and with even better decrease in treatment group than that in control group (P<0.05) .
3. The LVEF, LVESV and FS was improved significantly in both groups after treatment (P< 0.05),but the improvement in treatment group was more significant than that in control group (P<0.05) . After treatment, there was significant difference in treatment group with LVEDV than that before treatment (P<0.05) , but with no significant difference in control group (P>0.05) .
4. After treatment, the distance of 6MWT was increased signifieantly in both groups (P<0.05) ,and with even better increase in treatment group than that in control group (P<0.05) .
5. After treatment, the concentration of NT-proBNP and Copeptin was decreased significantly in both groups (P<0.05) ,and with even better decrease in treatment group than that in control group (P<0.05) .
6. After treatment, the marks of MLHFQ was decreased significantly in both groups (P<0.05) ,and with even better decrease in treatment group than that in control group (P<0.05) .
7. No side-effects such as the liver and kidney function damage were recorded in both groups.
Conclusions: 1. Jian Xin Soup could strengthen the therapeutic effects, improve heart function, enhance exercise performance and life quality, and it has cooperative function with conventional western medicine on CHF treatment.
2. Jian Xin Soup could decrease the level of NT-proBNP and Copeptin, and it may suggest that Jian Xin Soup is effective in the treatment of CHF.
3. Jian Xin Soup has no side effects, and it is very safe in six weeks.
Objective: To investigate the effects of Jian Xin Soup on heart function and left ventricular remodeling in order to find some possible mechanism and provide evidence to clinical application.
Methods: 76 model rats with CHF were randomly divided into 4 groups, that is, Jian Xin Soup low dose group, Jian Xin Soup high dose group, HF control group, and Perindopril group, 19 in each group. Another 15 rats are the sham operation group. In Jian Xin Soup low dose group, each rat is fed with 7.65g/kg; in Jian Xin Soup high dose group with Jian Xin Soup 15.30g/kg, and in Perindopril group with Perindopril 0.72mg/kg, Sham operation group and the control group is fed with 1ml/kg water. All rats were fed twice a day for 6 weeks. The measurement included: (1) mortality, body weight, total heart mass indexes(THMI),and left ventricular mass indexes(LVMI) were observed; (2) before and after the treatment, the IVST, LVPWT, LVEDD, FS, LVEF were recorded by Echocardiography; (3) pathologic changes of left ventricular myocardium were viewed with HE staining method; (4) collagen volume fraction (CVF) was done with patho-image analytical system; Expression of collagen type I and III was measured by immuno-hisochemical method, and the ratio of collagen type I and III was calculated; (5) concentration of AngII and ET in left ventricular myocardium was measured by radio-immunity method, the level of plasma NT-proBNP was measured by ELISA assay. The levels of ET and NT-proBNP mRNA in left ventricular myocardium were measured by RT-PCR; (6) the expression of p-ERK_(1/2) and p38-MAPK in left ventricular myocardium was measured by Western blot.
Results: 1. After the medication treatment, the mortality, THMI and LVMI were significantly decreased in those of all treatment groups (P< 0.05) , but there was no obvious difference among the treatment groups (P>0.05) .
2. Compared to sham operated group, in HF control group LVEDD was obviously increased and FS LVEF was decreased (P<0.05) ; After treatment, heart function improved compared to that of HF control group(P<0.05) , FS and LVEF were better in Jian Xin Soup high dose group and Perindopril group than those in Jian Xin Soup low dose group.
3. After the treatment of Jian Xin Soup, the pathomorphology of myocardium had been improved with dose-dependence, they were better in Jian Xin Soup high dose group and Perindopril group than those in Jian Xin Soup low dose group, but there was no obvious difference between Jian Xin Soup high dose group and Perindopril group.
4. After the medication treatment, the levels of type I collagen, ratio of collagen type I and III and CVF were significantly decreased in all treatment groups (P<0.05), lower in Jian Xin Soup high dose group and Perindopril group than that in Jian Xin Soup low dose group.
5. After the medication treatment, the level of AngII, ET and NT-proBNP were significantly decreased in all treatment groups (P< 0.05), but the level of AngII was the lowest in Perindopril group compare to that in the other two groups (P<0.05) . The levels of ET and NT-proBNP were lower in Jian Xin Soup high dose group and Perindopril group than those in Jian Xin Soup low dose group, but there was no obvious difference between Jian Xin Soup high dose group and Perindopril group (P>0.05) .
6. After the medication treatment, the levels of p-ERK_(1/2) and p38-MAPK were significantly decreased in all treatment groups (P< 0.05) , but the levels of p-ERK_(1/2) and p38-MAPK were lower in Jian Xin Soup high dose group and Perindopril group than those in Jian Xin Soup low dose group, but there was no obvious difference between Jian Xin Soup high dose group and Perindopril group (P>0.05) .
Conclusions: 1. Jian Xin Soup may be effective in the treatment of CHF through improving the CHF rats' heart function and tissue morphology.
2. Jian Xin Soup could decrease the level of type I collagen, ratio of collagen type I and III and CVF, it may regress ventricular remodeling through reversing collagen remodeling.
3. Jian Xin Soup could decrease the level of AngII, ET and NT-proBNP, it may regress ventricular remodeling through restraining over-excitation of nerve endocrine system.
4. Jian Xin Soup could decrease the level of p-ERK_(1/2) and p38-MAPK, it may regress ventricular remodeling through regulating the abnormal signal pathway of ERK and p38.
5. Jian Xin Soup could improve heart function and regress ventricular remodeling. There was no obvious difference in therapeutic effects between Jian Xin Soup and Perindopril in six weeks.
引文
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会。慢性心力衰竭诊断治疗指南。中华心血管病杂志,2007,35(12):1076-1093。
[2]Hunt SA.ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult:a report of the American College Cardiology / America Heart Association task force on practice guidelines.Circulation,2005,112(12):154-235.
[3]顾东风,黄广勇,何江。中国心力衰竭流行病学调查及其患病率。中华心血管病杂志,2003,31(1):3-5。
[4]Stumpf C,Petzi S,Seybold K,et al.Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial function.Clin Sci,2009,116(1):45-52.
[5]Braunwald E,Bristow MR.Congestive heart failure:fifty years of progress.Circulation,2000,102(20):14-23.
[6]杜杏坤,黎波。浅议中医药在心血管系统疾病中的应用。辽宁中医药大学学报,2008,10(12):18-20。
[7]Mckee PA,Castell WP,Mcnamara PM,et al.The natural history of congestive heart failure,the Framingham study.N Engl J Med,1971,285(26):1441-1446.
[8]陈灏珠。实用内科学。第12版,北京:人民卫生出版社,2006:1339。
[9]Lee DC,Johnson RA,Bingham JB,et al.Heart failure in our patients,a randomized trial of digoxin versus placebo.N Engl Med,1982,306(12):99-705.
[10]郑筱萸。中药新药临床研究指导原则。第一版,北京:中国医药科技出版社。2002:77-85。
[11]Guyatt GH,Sullivan MJ,Thomopson PJ,et al.The 6-minute walk:a new measure of exercise capacity in patients with chronic heart failure.Can Med Assoc,1985,32(8):919-923.
[12]The American Thoracic Society.ATS statement:guidelines for the six-minute walk test.Am J Respir Crit Care Med,2002,166(1):111-117.
[13]Rector TS,Cohn JN.Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire:reliability and validity during a randomized,double-blind,placebo-controlling trial of pimobendan.Pimobendan Multicentre Research Group.Am Heart J,1992,12(4):1017-1025.
[14]Cooper KH.A mean of assessing maximal oxygen intake.Correlation between field and treadmill testing.JAMA,1968,203(3):201-204.
[15]中华心血管病杂志编辑委员会心血管药物对策专题组。心血管药物临床试验评价方法建议。中华心血管病杂志,1998,26(6):405-413。
[16]Task force for the diagnosis and treatment of chronic heart failure European society of cardiology Guidelines for the diagnosis and treatment of chronic heart failure.Eur Heart,2001,22(17):1527-1560.
[17]Schaufelberger M,Swedberg K.Is 6-minute walk test of value in congestive heart failure? Am Heart J,1998,136(3):371-372.
[18]Bittner V,Weiner DH,Yusuf S,et al.Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction.SOLVD Investigators.JAMA,1993,270(14):1702-1707.
[19]Tor T,Kubo S,Cohn J.Patients self-assessment of their congestive heart failure.Part2:content,reliability and validity of a new measure,the Minnesota Living with Heart Failure Questionnaire.Heart Failure,1987;3:198-209.
[20]Cowley A J,Wiens B L,Segal R,et al.Randomised comparison of Losartan vs Captopril on quality of life in elderly patient with symptomatic heart failure:the Losartan heart failure ELITE quality of life sub-study.Qual Life Res,2000,9(4):377-384.
[21]Morcillo C,Aguado O,Delas J,et al.Utility of the Minnesota Living With Heart Failure Questionnaire for assessng qulaity of life in heart failure patients.Rev Esp Cardiol,2007,60(10):1093-1096.
[22]Ulrich S,Speich R,Domenighetti G,et al.Bosentan therapy for chronic thromboembolic pulmonary hypertension,A national open label study assessing the effect of Bosentan on haemodynamics,exercise capacity,quality of life,safety and tolerability in patients with chronic thromboembolic pulmonary hypertension(BOCTEPH-Study).Swiss Med Wkly,2007,137(41-42):573-580.
[23]Cleland JG,Calvert MJ,Verboven Y,et al.Effects of cardiac resynchronization therapy on long-term quality of life:an analysis from the Cardiac Resynchronisation-Heart Failure(CARE-HF) study.Am Heart J,2009,157(3):457-466.
[24]Alla F,Briancon S,Guillemin F,et al.Self-rating of quality of life provides additional prognostic information in heart failure.Insights into the EPICAL study.Eur J Heart Fail,2002,4(3):337-343.
[25]Task force for the diagnosis and treatment of chronic heart failure of European society of cardiology.Guideline for the diagnosis and treatment of chronic heart failure.Eur Heart J,2001,22:1527-1560.
[26]汪林,朱文玲,陈连凤,等。心力衰竭患者治疗中的血浆氮末端-前体脑钠肽浓度。中华内科杂志,2005,44(3):177-179。
[27]Troughton RW,Frampton CM,Yandle TG,et al.Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide(NT-proBNP)concentration].Lancet,2000,355(9210):1126-1130.
[28]Miller WL,Hartman KA,Grill DE,et al.Only large reductions in concentrations of natriuretic peptides(BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure.Clin Chem,2009,55(1):78-84.
[29]Omland T,de lemos JA.Amino-terminal pro-B-type natriuretic peptides in stable and unstable ischemic heart diseases.Am J Cardiol,2008,101(3A):67-71.
[30]Schou M,Gustafsson F,Kistorp CN,et al.Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure.Am J Cardiol,2007,100(10):1571-1576.
[31]Morqenthaler NG,Struck J,Jochberqer S,et al.copeptin:clinical use of a new biomarker.Trends Endocrinol Metab,2008,19(2):43-49.
[32]Bhandari SS,Loke I,Davies JE,et al.Gender and renal function influence plasma levels of copeptin in healthy individuals.Clin Sci(Lond),2009,116(3):257-263.
[33]Fenske W,Stork S,Blechschmidt A,et al.Copeptin in the differential diagnosis of hyponatremia.J Clin Endocrinol Metab,2009,94(1):123-129.
[34]Neuhold S,Huelsmann M,Strunk G,et al.Comparison of copeptin,B-type natriuretic peptide,and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure:prediction of death at different stage of the disease.J Am Coll Cardiol,2008,52(4):266-272.
[35]Kelly D,Squire IB,Khan SQ,et al.C-terminal provasopressin(copeptin) is associated with left ventricular dysfunction,remodeling,and clinical heart failure in survivors of myocardial infarction.J Card Fail,2008,14(9):739-745.
[36]Stoiser B,Mortl D,Hulsmann M,et al.Copeptin,a fragment of the vasopressin precursor,as a novel predictor of outcome in heart failure.Eur J Clin Invest,2006,36(11):771-778.
[37]Geqenhuber A,Struck J,Dieeplinqer B,et al.Comparative evaluation of B-type natriuretic peptide,mid-regional pro-A-type natriuretic peptide,mid-regional pro-adrenomedullin,and Copeptin to predict 1-yeart mortality in patients with acute destabilized heart failure.J Card Fail,2007,13(1):42-49.
[38]Voors AA,von Haehling S,Anker SD,et al.C-terminal provasopressin (copeptin) is a strong prognostiv marker in patients with heart failure after an acute myocardial infarction:results from the OPTIMAAL study.Eur Heart J,2009 Apr 3,Epub ahead of print.
[39]Khan SQ,Dhillon OS,O'Brien RJ,et al.C-terminal provasopressin(copeptin)as a novel and prognostic marker in acute myocardial infarction:Leicester Acute Myocardial Infarction Peptide(LAMP) study.Circulation,2007,115(16):2103-2110.
[40]Cicoira M,Bolger AP,Doehner W,et al.High tumor necrosis factor-alpha levels are associated with exercise intolerance and neuro-hormonal activation in chronic heart failure patients.Cytokine,2001,15(2):80-86.
[41]Hsu CP,Huang CY,Wang JS,et al.Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.Ann Thorac Surg,2008,86(4):1243-1249.
[42]Westermann D,Riad A,Lettau O,et al.Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure.Hypertension,2008,52(6):1068-1075.
[43]周文武,林玲,陈军等。冠脉结扎法制作大鼠心肌缺血模型。中国实验动物学报,2004,12(4):226-229。
[44]徐叔云,卞如濂,陈修。药理实验方法学。第三版,北京:人民卫生出版社,2001:179。
[45]Miqrino RQ,Zhu X,Morker M,et al.Myocardial dysfunction in the periinfarct and remote regions following anterior infarction in rats quantified by 2D radial strain echocardiography:an observational cohort study.Cardiovasc Ultrasound,2008,29(6):17.
[46]黄国倩,刘虹,舒先红,等。超声心动图评价粒细胞集落刺激因子动员自身骨髓干细胞对心肌梗死后左心室重构及心功能的影响。中华超声影像学杂志,2004,13(11):848-852。
[47]Schwarz ER,Pollick C,Dow J,et al.A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res, 1998,39(1):216-223.
[48] Kanno S, Lemer DL, Schuessler RB, et al. Echocardiographic evaluation of ventricular remodeling in a mouse model of myocardial infarction. J Am Soc Echocardiogr, 2002,15(6):601 -609.
[49] Scherrer CM, Steudel W, Hunziker PR, et al. Three-dimensional echocardiographic assessment of left ventricular wall motion abnormalities in mouse myocardial infarction. J Am Soc Echocardiogr, 1999,12(10):834-840.
[50] Yaoita H, Sakabe A, Maehara K, et al. Different effects of carvedilol,metoprobol and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation, 2002,105(8):975-980.
[51] Brog KT, Caulfiele B. The collagen matrix of heart. Fed Proc, 1981,40(7):2037-2041.
[52] Weber KT, Eghbali M. Collagen and the myocardium: fibrilar structure,biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem, 1990, 96(1): 1-14.
[53] Juan W, Nakazawa M, Watanabe K, et al. Quinapril inhibits progress of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. Mol Cell Biochem, 2003,251(1-2):77-82.
[54] Umar S, Bax JJ, Klok M, et al. Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy. Eur J Heart Fail,2008,100(9):878-883.
[55] Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypetens,2007,9(7):546-550.
[56] Zhang P, Yang YJ, Chen X, et al. Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2005,27(1):53-61.
[57] Nishikawa N, Masuyama T, Yamamoto K, et al. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol, 2001,38(5):1539-1545.
[58] Matsumoto R, Yoshiyama M, Omura T, et al. Effects of aldosterone receptor antagonist and angiotensin type I receptor bolocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction. Circ J, 2004,68(4):376-382.
[59] Jirmar R, Pelouch V, Widimsky P, et al. Infuluence of primary coronary intervention on myocardial collagen metabolism and left ventricle remodeling predicted by collagen metabolism markers. Int Heart J, 2005,46(6):949-959.
[60] Angoulvant D, Fazel S, Weisel RD, et al. Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-deficient mice. J Thorac Cardiovasc Surg, 2009,137(2):471-480.
[61] Cerisano G, Parodi G, Dovellini EV, et al. Time course of serum collagen types I and III metabolism products after reperfused acute myocardial infarction in patients with and without systemiv hypertension. J Hum Hypertens, 2009,23(1):40-47.
[62] Radovan J, Vaclav P, Petr W, et al. Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction. Mol Cell Biochem,2006,293(1-2):71-78.
[63] Wei S, Chow LT, Shum IO, et al. Left and right ventricular collagen type I/III ratios and remodeling post-myocardial infarction. J Card Fail, 1999,5(2):117-126.
[64] Gomes MC, Ferreira A, Bettencourt P. Physiopathology of heart failure. Rev Port Cardiol, 2004,23(2):117-123.
[65] Gheorghiade M, De Luca L, Bonow RO. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am J Cardiol, 2005,96(12A):3-9.
[66] Spinarova L, Spinar J, Vasku A, et al. Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients.Exp Mol Pathol, 2008,84(3):251-255.
[67] De Bold AJ, de Bold ML. Determinants or natriuretic peptide production by the heart: basic and clinical implications. J Investig Med, 2005,53(7):371-377.
[68] Barra S, Vitagliano A, Cuomo V, et al. Vascular and metabolic effects of angiotensin II receptor blockers. Expert Opin Pharmacother, 2009,10(2):173-189.
[69] 张婷,崔颖。心血管疾病治疗新靶点。中国新药杂志, 2001, 40(5): 338-340。
[70] Aranguix-Urroz P, Soto D, Contreras A, et al. Differential participation of angiotensin II type 1 and 2 receptors in the regulation of cardiac cell death triggered by angiotensin Ⅱ.Am J Hypertens,2009(Epub ahead of print).
[71]Krum H,Abraham WT.Heart failure.Lancet,2009,373(9667):941-955.
[72]Reddy HK,Campbell SE,Janicki JS,et al.Coronary microvascular fluid flux and permeability influence of angiotensin Ⅱ aldosterone and arterial hypertension.J Lab Clin Meal,1993,121(3):510-521.
[73]周玉杰,汪丽蕙,柯元南,等。碱性成纤维细胞生长因子对血管平滑肌细胞及内膜损伤后血管Ⅰ及Ⅲ型胶原mRNA表达的影响。中华心血管病杂志,1998,26(1):59-61。
[74]Crabos M,Roth M,Hahn AW,et al.Characterization of angiotensin Ⅱ receptors in cultured adult rat cardiac fibroblasts.J Clin Invest,1994,93(6):2372-2378.
[75]Brilla CG,Zhou G,Matsubara L,et al.Collagen metabolism in cultured adult rat cardiac fibroblasts:response to angiotensin Ⅱ and aldosterone.J Mol Cell Cardiol,1994,26(7):809-820.
[76]叶刚,陈尚恭,陈孟琴,等。心肌局部肾素-血管紧张素系统在心肌缺血及再灌注损伤时的激活及Losartan的保护作用。高血压杂志,1996,4(3):178-181。
[77]Lijnen PJ,Petrov VV.Role of intracardiac rennin-angiotensin-aldosterone syetem in extracellular matrix remodeling.Methods Find Exp Clin Pharmacol,2003,25(7):541-564.
[78]Gombos T,Forhecx Z,Pozsonyi Z,et al.Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure.Inflamm Res,2009(Epub ahead of print).
[79]Adlbrecht C,Hulsmann M,Strunk G,et al.Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure.Eur J Heart Fail,2009(Epub ahead of print).
[80]Schorlemmer A,Matter ML,Shohet RV.Cardioprotective signaling by endothelin.Trends Cardiovasc Med,2008,18(&):233-239.
[81]Bras Silva C,Leite Moreira AF.Myocardial effects of endothelin-1.Rev Port Cardiol,2008,27(7-8):925-951.
[82]Bras-Silva C,Leite-Moreira AF.Myocardial effects of endothelin-1.Rev Port Cardiol,2008,27(7-8):925-951.
[83]Lee CS,Tkacs NC.Current concepts of neurohormonal activation in heart failure:mediators and mechanisms.AACN Adv Crit Care,2008,19(4):364-385.
[84]Boldanoa T,Noveanu M,Breidthardt T,et al.Impact of history of heart failure on diagnostic and prognostic value of BNP:results from the B-type natriuretic peptide for acute shortness of breath evaluation(BASEL) study.Int J Cardiol,2009 Jan 28.[Epub ahead of print]
[85]Zuber M,Cuculi F,Jost CA,et al.Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure.Scand Cardiovasc J,2009,26:1-6.
[86]Sakata K,Iida K,Mochiduki N,et al.Brain natriuretic peptide(BNP) level is closely related to the extent of left ventricular sympathetic overactivity in chronic heart failure.2009,48(6):393-400.
[87]Novo G,Amoroso GR,Fazio G,et al.Biomarkers in heart failure.Front Biosci,2009,14:2484-2493.
[88]Lainscak M,von Haehling S,Anker SD.Natriuretic peptides and other biomarkers in chronic heart failure:from BNP,NT-proBNP and MR-proBNP to routine biochemical markers.Int J Cardiol,2009,132(3):303-311.
[89]Clerk A,Sugden PH.Inflame my heart(by p38-MAPK).Circ Res,2006,99(5):455-458.
[90]Liu YH,Wang D,Rhaleb NE,et al.Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction.J Card Fail,2005,11(1):74-81.
[91]Frantz S,Behr T,Hu K,et al.Role of p38 mitogen-activated protein kinase in cardiac remodeling.Br J Pharmacol,2007,150(2):130-135.
[92]杨丽霞,王先梅,石燕昆,等。细胞外信号调节激酶的变化在心力衰竭患者心肌重构中的意义。心脏杂志,2006,18(1):62-64。
[93]Bueno OF,De Windt LJ,Lim HW,et al.The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.Circ Res,2001,88(1):88-96.
[94]Ueyama T,Kawashima S,Sakoda T,et al.Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.J Mol Cell Cardiol,2002,32(6):947-960.
[95]Liu J,Wu LL,Li L,et al.Growth promoting effect of platelet-derived growth factor on rat cardiac mycytes.Regul Pept,2005,127(1-3):11-18.
[96]Clerk A,Aggeli IK,Stathopoulou K,et al.Peptide growth factors signal differentially through protein kinase C to extracellular signal regulated kinases in neonatal cardiomyocytes.Cell Signal,2006,18(2):225-235.
[97]Das A,Xi L,Kukreja RC.Protein kinase G-dependent cardio-protective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta.J Biol Chem,2008,283(43):29572-29585.
[98]Baines CP,Molkentin JD.Stress signaling pathways that modulate cardiac myocyte apoptosis.J Mol Cell Cardiol,2005,38(1):47-62.
[99]Niizeki T,Takeishi Y,Arimoto T,et al.Cardiac specific over-expression of diacylglycerol kinase zeta attenuates left ventricular remodeling and improves survival after myocardial infarction.Am J Physiol Heart Circ Physiol,2007,292(2):1105-1112.
[100]Yasaka A,Hayashida W.Alterations of load-induced p38 MAP kinase activation in failing rat hearts.Biochem Biophys Res Commun,2001,285(2):503-507.
[101]Lymperopoulos A,Renqo G,Zincarelli C,et al.An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin Ⅱ-induced aldosterone production in vitro and in vivo.Proc Natl Acad Sci USA,2009,106(14):5825-5830.
[102]Boer RA,Pokharel S,Flesch M,et al.Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin Ⅱ driven progression towards overt heart failure in homozygous TGR(mRen2)27.J Mol Med,2004,82(10):678-687.
[103]Liang FQ,Lu S,Gardner DG,et al.Endothelin dependent and independent components of strain activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen activated protein kinase.Hypertension,2000,35(2):188-192.
[104]孙宁玲,王鸿懿,陈源源,等。ERK表达及活化在自发性高血压大鼠心肌肥厚中作用的研究。高血压杂志,2002,10(4):252。
[105]Aoki H,Richmond M,Tzumo S,et al.Specific role of the extracellular signal-regulated kinase pathway in angiotensin Ⅱ-induced cardiac hypertrophy in vitro.Biochem J,2000,347(1):275-284o
[106]王晋明,张庆华,王芳,等。厄贝沙坦和咪达普利对高血压大鼠心肌细胞外信号调节激酶的影响。中华心血管病杂志,2002,30(6):342-345。
[107]杨丽霞,王先梅,石燕昆,等。细胞外信号调节激酶的变化在心力衰竭患者心肌重构中的意义。心脏杂志,2006,18(1):62-64。
[108]Liang Q,Elson AC,Gerdes AM.p38 MAP kinase activity is correlated with angiotensin Ⅱ type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats. J Card Fail,2006,12(6): 479-486.
[109] Clerk A, Cullingford TE, Fuller SJ, et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol,2007,212(2):311-322.
[110] Hag S, Choukroun G, Lim H, et al. Differentia activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure.Circulation, 2001,103(5):670-677.
[111] Ng DC, Court NW, dos Remedios CG, et al. Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts. Cardiovasc Res, 2003,57(2):333-346.
[112] Freed DH, Borowiec AM, Angelovska T, et al. Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways. Cardiovasc Res, 2003,60(2):365-375.
[113]Takahashi K, Fukushima S, Yamahara K, et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart.2008,118(14):106-114.
[114] Frantz S, Behr T, Hu K, et al. Role of p38-MAPK inhibtors in the treatment of ischemic heart disease. Pharmacol Ther, 2007,116(2): 192-206.
[115] Liu YH, Wang D, Rhaleb NE, et al. Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. J Card Fail, 2005,11(1):74-81.
[116]Tenhunen O, Soini Y, lives M, et al. p38 kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms. Faseb J, 2006,20(11):1907-1909.
[117] See F, Thomas W, Way K, et al. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol, 2004,44(8): 1679-1689.
[118] Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibtors in the treatment of ischaemic heart disease. Pharmacol Ther, 2007,116(2): 192-206.
[119] Kyoi S, Otani H, Matsuhisa S, et al. Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc Res, 2006,69(4):888-898.
[1]Cooper KH.A means of assessing maximal oxygen intake.Correlation between field and treadmill testing.JAMA,1968,203(3):201-204.
[2]Lisboa BC,Barria PP,Yanez VJ,et al.Six minutes walk for the assessment of patients with chronic obstructive pulmonary disease.Rev Med Chil,2008,136(8):1056-1064.
[3]李娜,邱晨,魏永丽。六分钟步行实验与慢性阻塞性肺疾病患者肺功能的关系。中国组织工程研究与临床康复,2008,12(11):2116-2119。
[4]Jehn M,Schrnidt TA,Schuster T,et al.Daily walking performance as an independent predictor of advanced heart failure:prediction of exercise capacity in chronic heart failure.Am Heart J,2009,157(2):292-298.
[5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会。慢性心力衰竭诊断治疗指南。中华心血管病杂志,2007,35(12):1076-1093。
[6]中华心血管病杂志编辑委员会心血管药物对策专题组。心血管药物临床试验评价方法建议。中华心血管病杂志,1998,26(6):405-413。
[7]Boxer RS,Wang Z,Walsh SJ,et al.The utility of the 6-minute walk test as a measure of frailty in older adults with heart failure.Am J Geriatr Cardiol,2008,17(1):7-12.
[8]Task force for the diagnosis and treatment of chronic heart failure European society of cardiology Guidelines for the diagnosis and treatment of chronic heart failure.Eur Heart,2001,22(17):1527-1560.
[9]Foley PW,Stegemann B,Smith RE,et al.Cardiac resynchronization therapy in patients with mildly impaired left ventricular function.Pacing Clin Electrophysiol,2009,Suppl1:S186-189.
[10]Raymond Lee,Yiong HC,Jennifer W,et al.The 6-minute walk test predicts clinical outcome in Asian patients with chronic congestive heart failure on contemporary medical therapy:a study of the multiracial population in Singapore.International Cardio,2007,119(2):168-175.
[11]Guyatt GH,Sullivan MJ,Thompson PJ,et al.The 6-minute walk:a new measure of exercise capacity in patients with congestive heart failure.Can Med Assoc,1985,32(8):919-923.
[12]Bittner V,Weiner DH,Yusuf S,et al.Prediction of mortality and morbidity with a 6-minute test in patients with left ventricular dysfunction.SOLVD Ivestigators.JAMA,1993,270(14):1702-1707.
[13]陈协兴,洪华山,陈良龙,等。慢性心力衰竭患者6min步行距离与血清脑钠肽水平的临床研究。中国临床药理学与治疗学,2004,9(5):561-564。
[14]慧海鹏,许顶立,李琦,等。六分钟步行对充血性心力衰竭患者QT离散度的影响。中国现代医学杂志,2002,12(16):47-48。
[15]The American Thoracic Society.ATS statement:guidelines for the six-minute walk test.Am J Respir Crit Care Med,2002,166(1):111-117.
[16]王惠兰,刘乾惠,李雪红。鼓励因素对心力衰竭患者六分钟步行实验的影响。中国临床康复,2004,8(30):6550-6551。
[17]Laterence P,Cahalin MA,Michael A,et al.The six minutes walk test predicts peak oxygen uptake and survival in patients with advanced heart failure.Chest,1996,110(3):325-332.
[18]Opasich C,Pinna GD,Mazza A,et al.Reproducibility of the six-minute walking test in patients with congestive heart failure:practical implications.Am J Cardiol,1998,81(12):1497-500.
[19]Demers C,Mckelvie RS,Negassa A,et al.Reliability,validity and responsiveness of the six-minute walk test in patients with heart failure.Am Heart J,2001,142(4):698-703.
[20]蒙涛,曹加淮,李江津,等。慢性心力衰竭患者运动训练的临床意义。中国现代药物应用,2008,2(1):43-44。
[21]Zugck C,Kruger C,Durr S,et al.Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J,2000,21(7):540-549.
[22]冷秀玉,曾武涛,陈国伟等。6分钟步行实验与慢性心力衰竭。中国心血管杂志,2003,8(6):412-413。
[23]Arslan S,Erol MK,Gundoqdu F,et al.Prognostiv value of 6-minute walk test in stable outpatients with heart failure.Tex Heart Inst J,2007,34(2):166-169.
[24]Cahalin LP,Mathier MA,Semigran MJ,et al.The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure.Chest,1996,110(2):325-332.
[25]Peeters P,Mets T.The 6-minute walk as appropriate exercise test in elderly patients with chronic heart failure.Gerontol A Biol Sci,1996,51(4):147-151.
[26]Chien CL,Lee CM,Wu YW,et al.Home-based exercise increases exercise capacity but not quality of life in people with chronic heart failure:a systematic review.Aust J physiother,2008,54(2):87-93.
[27]Haass M,Zuqck C,Kubler W.The 6 minute walking test:a cost-effective alternative to spiro-ergometry in patients with chronic heart failure? Z Kardiol,2000,89(2):72-80.
[28]Alahdab MT,Mansour IN,Napan S,et al.Six minute walk test predicts long-term all-cause mortality and heart failure rehospitalization in African-American patients hospitalized with acute decompensated heart failure.2009,15(2):130-135.
[29]Zuqck C,Kruqer C,Durr S,et al.Is the 6 minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J,2000,21(7):507-508.
[30]Shah MR,Hasselblad V,Gheorghiade M,et al.Prognostic usefulness of six-minute walk in patients with advanced congestive heart failure secondary to ischemic of non-ischemic cardiomyopathy.Am J Cardiol,2001,88(9):987-993.
[31]Roul G,Germain P,Bareiss P,et al.Does the 6-minute walk test predict the prognosis in patients with NYHA class Ⅱ or Ⅲ chronic heart failure? Am Heart J,1998,136(3):449-457.
[32]Frankenstein L,Zuqck C,Nelles M,et al.Sex-specific predictive of 6-minute walk test in chronic heart failure is not enhanced using percent achieved of published reference equations.J Heart Lung Transplant,2008,27(4):427-434.
[33]Zhou SP,Yang CM,Shi WB,et al.Study on six-minute walk test and cardiac output response against exercise in patients with chornic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi, 2008,36(3):236-239.
[34]Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces does related improvements in left ventricular function an survival in subjects with chronic heart failure. Circulation, 1996,94( 11 ):2807-2816.
[35]Gualeni A, Aloia AD, Gentiliui A, et al. Effects of maximally tolerated oral therapy on the six-minute walking test in patients with chronic congestive heart failure secondary to either ischemic or idiopathic dialated cardiomyopathy. Am J Cardiol, 1998,81(11): 1370-1372.
[36]Kum LC, Yip GW, Lee PW, et al. Comparison of angiotensin-converting enzyme inhibitor along and in combination with irbesartan for the treatment of heart failure. Int J Cardiol, 2008,125(1): 16-21.
[37]Sisakian H, Torqomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischemic cardiomyopathy. Acta Cardiol, 2007,62(5):493-499.
[38]Chwyczko T, Sterlinski M, Maciaq A, et al. Impact of cardiac resynchronization the therapy on adaption of circulatory and respiratory systems to exercise assessed by cardiopulmonary exercise test in patients with chronic heart failure.Kardiol Pol, 2008,66(4):406-414.
[39] Sterlinski M, Maciaq A, Kowalski 0, et al. Mortality in patients with heart failure treated with cardiac resynchronization therapy. A long-term multi-centre follow-up study. Kardiol Pol, 2007,65(11):1287-93.
[40]Foley PW, Steqemann B, Smith RE, et al. Cardiac resynchronization therapy in patients with mildly impaired left ventricular function. Pacing Clin Electrophysiol,2009,32 Supp11:S186-189.
[41]Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol, 2008,52(15):1239-1246.
[42]Macias A, Gavira JJ, Castano S, et al. Left ventricularu pacing site in cardiac resynchronization therapy: clinical follow-up and predictors of failed lateral implant. Eur J Heart Fail, 2008,10(4):421-427.
[43]Foray A, Williams D, Reemtsma K, et al. Assessment of sub-maximal exercise capacity in patients with left ventricular assist devices. Circulation, 1996,94(9 suppl):II 222-226.
[44]Auricchio A,Stellbrink C,Sack S,et al.The pacing therapies for congestive heart failure(PATH-CHF) study:rationale,design,and endpoints of a prospective randomized multicentre study.Am J Cardiol,1999,83(5B):130D-135D.
[45]Hoijer CJ,Meurling C,Brandt J.Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure:a double-blind,randomized crossover study.Europace,2006,8(1):51-55.
[46]Jaski BE,Jessup ML,Mancini DM,et al.Calcium upregulation by percutaneous administration of genen therapy in cardiac disease(CUPID Trial),a first-in-human phase 1/2 clinical trial.J Card Fail,2009,15(3):171-181.
[47]Meyer K,Schwaibold M,Westbrook S,et al.Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure.Am Heart J,1997,133(4):447-453.
[48]Piepoli MF,Capucci A.Exercise training in heart failure:effect on morbidity and mortality.Int J Cardiol,2000,73(1):3-6.
[49]Jankowska EA,Weqrzynowska K,Superlak M,et al.The 12-week progressive quadriceps resistance training improves muscle strength,exercise capacity and quality of life in patients with stable chronic heart failure.Int J Cardiol,2008,130(1):36-43.
[50]Dracup K,Evangelista LS,Hamilton MA,et al.Effects of a home-based exercise program on clinical outcomes in heart failure.Am Heart J,2007,154(5):877-883.
[51]许顶立,慧海鹏,侯玉清,等。步行运动对充血性心力衰竭患者血浆可溶性炎性细胞因子和氧化应激的影响。中华心血管病杂志,2001,29(7):406-409。
[52]慧海鹏,许顶立,侯玉清,等。充血性心力衰竭患者运动前后血浆细胞间黏附分子-1含量及临床意义。岭南心血管病杂志,2001,7(6):415-417。
[53]王艳,刘应才,张泽芳,等。6分钟步行实验对心力衰竭患者白细胞介素10和肿瘤坏死因子α水平的影响。中国煤炭工业医学杂志,2004,7(5):394-395。
[54]王兵,许顶立,侯玉清,等。六分钟步行运动训练对慢性心力衰竭患者血浆肾素和血管紧张素Ⅰ的影响。中国循环杂志,2002,17(4):266-268。
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会。慢性心力衰竭诊断治疗指南。中华心血管病杂志,2007,35(12):1076-1093。
[2]Rich MW.Heart failure in older adults.Med Clin North Am,2006,90(5):863-885.
[3]Chandrashekhar Y.Role of apoptosis in ventricular remodeling.Curr Heart Fail Rep,2005,2(1):18-22.
[4]Ibe W,Saraste A,Lindemann S,et al.Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodeling in dilated cardiomyopathy,but is not affected by growth hormone treatment.Eur J Heart Fail,2007,9(2):160-167.
[5]Okada H,Takemura G,Kosai K,et al.Combined therapy with cardio-protective cytokine administration and anti-apoptotic gene transfer in post-infarction heart failure.Am J Physiol Heart Circ Physiol,2009,296(3):H616-626.
[6]Wang GY,Bergman MR,Nguyen AP,et al.Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility.Cardiovasc Res,2006,69(3):688-696.
[7]Lakkis J,Lu WX,Weir MR.RAAS escape:a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep,2003,5(5):408-417.
[8] Zhang X, Yang YJ, Zhu WL, et al. Effects of angiotensin II receptor antagonism on matrix metalloproteinases and fibronectin in rats with experimental myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi, 2006,34(11):1029-1034.
[9] Gonzalez A, Lopez B, Diez J. Fibrosis in hypertensive heart disease: role of the rennin-angiotensin-aldosterone system. Med Clin North Am, 2004,88(1):83-97.
[10] Schroder D, Heger J, Piper HM, et al. Angiotensin II stimulates apoptosis via TGF-betal signaling in ventricular cardiomyocytes. J Mol Med, 2006,84(11):975-983.
[11] Yee DK, Suzuki A, Luo L, et al. Identification of structural determinants for G protein-independent activation of mitogen-activated protein kinases in the seventh trans-membrane domain of the angiotensin II type 1 receptor. Mol Endocrinol, 2006,20(8): 1924-1934.
[12]Paradis P, Dali YN, Paradis FW, et al. Over-expression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proe Natl Acad Sci USA, 2000,97(2):931-936.
[13]Rittenhouse SK. Spironolactone for heart failure: a worthy addition to therapy.Adv Nurse Prac, 2001,9(1):34-36.
[14] Martinez Reding J. Heart failure, neurohormonal treatment. Arch Cardiol Mex,2007,77(4): 106-110.
[15] Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J, 2008 Jun 27. [Epub ahead of print]
[16]Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol, 2001,37(5):1228-1233.
[17] Berry C, Murphy NF, De Vito G, et al. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail,2007,9(4):429-434.
[18]Xu G, Liu A, Liu X. Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules.Nephrology(Carlton),2008,13(8):694-701.
[19]Nishiyama A,Abe Y.Molecular mechanisms and therapeutic strategies of chronic renal injury:renoprotective effects of aldosterone blockade.J Pharmacol Sci,2006,100(1):9-16.
[20]Dash R,Schmidt AG,Pathak A,et al.Differential regulation of p38mitogen-activated protein kinase mediates gender-dependent catecholamine -induced hypertrophy.Cardiovasc Res,2003,57(3):704-714.
[21]曾欣,张元春。心脏胶原纤维增生及其影响因素。心血管病学进展,2003,24(4):303-306。
[22]Hamid T,Gu Y,Ortines RV,et al.Divergent tumor necrosis factor receptor-related remodeling response in heart failure:role of nuclear factor-kappaB and inflammatory activation.Circulation,2009,119(10):1386-1397.
[23]Mann DL.Recent insights into the role of tumor necrosis factor in the failing heart.Heart Fail Rev,2001,6(2):71-80.
[24]El AD,Zimlichman R,Mashiach Y,et al.Adenosine and TNF-alpha exert similar inotropic effect on heart cultures,suggesting a cardioprotective mechanism against hypoxia.Life Sci,2007,81(10):803-813.
[25]Sun M,Chen M,Dawood F,et al.Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.Circulation,2007,115(11):1398-1407.
[26]Wang M,Tsai BM,Crisostomo PR,et al.Tumor necrosis factor receptor 1signaling resistance in the female myocardium during ischemia.Circulation,2006,114(1):1282-1289.
[27]Yang LL,Gros R,Kabir MG,et al.Conditional cardiac over-expression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice.Circulation,2004,109(2):255-261.
[28]Schula R,Heusch G.Tumor necrosis factor-alpha and its receptors 1 and 2:Yin and Yang in myocardial infarction? Circulation,2009,119(10):1355-1357.
[29]Pagani FD,Baker LS,His C,et al.Left ventricular systolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.J Clin Invest,1992,90(2):389-392.
[30]Sun M,Chen M,Dawood F,et al.Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.Circulation,2007,115(11):1398-1407.
[31]Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation,1997,95(5):1247-1252.
[32]Flesch M, Hoper A, Delltalia L, et al. Activation and functional significance of the rennin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation, 2003,108(5):598-604.
[33]Berry MF, Woo YJ, Pirolli TJ, et al. Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J Hert Lung Transplant, 2004,23(9):1061-1068.
[34] Sihvola RK, Koskinen PK, Pulkkinen VP, et al. Inhibition of tumor necrosis factor-alpha attenuates myocardial remodeling in rat cardiac allografts. J Heart Lung Transplant, 2006,25(5):569-578.
[35]Mlyauchi T. Endothelin and heart failure. Nippon Rinsho, 2004,62(9): 648-654.
[36] Rivera M, Cortes R, Portoles M, et al. Plasma concentration of big endthelin-1 and its relation with plasma NT-proBNP and venteicular function in heat failure patients. Rev Esp Cardiol, 2005,58(3):278-284.
[37]Konstam MA, DeNofrio D. Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development. Circulation,2004,109(2):143-145.
[38]Stessel H, Brunner F. Effect of endothelin antagonism on contractility,intracellular calcium regulation and calcium regulatory protein expression in right ventricular hypertrophy of the rat. Basic Clin Pharmacol Toxicol, 2004,94(1):37-45.
[39]Oie E, Clausen OP, Yndestad A, et al. Endothelin receptor antagonism attenuates cardiomyocyte apoptosis after induction of ischemia rats. Scand Cardiovasc J,2002,36(2):108-116.
[40]Ito H, Hirata Y, Adachi S, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II induced hypertrophy in cultured rat cardiomyocytes. J Clin Ivest, 1993,92(1):398-403.
[41]Jolda MB, Salomon P. Cytokines and remodeling of the heart in patients with congestive heart failure. Pol Arch Med Wewn, 2003,109(1):23-33.
[42]Boglioni FV, Metra M, Locati M, et al. Role of inflammation mediators in the pathogenesis of heart failure. Ital Heart J Suppl, 2001,2(6)628-633.
[43]Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation, 2008,117(20):2670-2683.
[44]Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol,1999,83(1): 376-382.
[45]Pennica D, Shaw KJ, Swanson TA, et al. Cardiotrophin-1, Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J Biol Chem, 1995,270(18):10915-10922.
[46]Kunisada K, Hirota H, Fujio Y, et al. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation,1996,94(3):2626-2632.
[47]Feuerstein GZ, Bril A, Rufflo RR, et al. Protective effects of carvedilol in the myocardium. Am J Cardiol, 1999,83(2):376-380.
[48]Qanud K, Mamdani M, Pepe M, et al. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure. Am J Physiol Heart Circ Physiol,2008,295(5):2098-2105.
[49]Radovanovix S, Krotin M, Simic DV, et al. Markers of oxidative damage in chronic heart failure: role in disease progression. Redox Rep, 2008,13(3):109-116.
[2]Hunt SA.ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult:a report of the American College Cardiology / America Heart Association task force on practice guidelines.Circulation,2005,112(12):154-235.
[3]顾东风,黄广勇,何江。中国心力衰竭流行病学调查及其患病率。中华心血管病杂志,2003,31(1):3-5。
[4]Stumpf C,Petzi S,Seybold K,et al.Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial function.Clin Sci,2009,116(1):45-52.
[5]Braunwald E,Bristow MR.Congestive heart failure:fifty years of progress.Circulation,2000,102(20):14-23.
[6]杜杏坤,黎波。浅议中医药在心血管系统疾病中的应用。辽宁中医药大学学报,2008,10(12):18-20。
[7]Mckee PA,Castell WP,Mcnamara PM,et al.The natural history of congestive heart failure,the Framingham study.N Engl J Med,1971,285(26):1441-1446.
[8]陈灏珠。实用内科学。第12版,北京:人民卫生出版社,2006:1339。
[9]Lee DC,Johnson RA,Bingham JB,et al.Heart failure in our patients,a randomized trial of digoxin versus placebo.N Engl Med,1982,306(12):99-705.
[10]郑筱萸。中药新药临床研究指导原则。第一版,北京:中国医药科技出版社。2002:77-85。
[11]Guyatt GH,Sullivan MJ,Thomopson PJ,et al.The 6-minute walk:a new measure of exercise capacity in patients with chronic heart failure.Can Med Assoc,1985,32(8):919-923.
[12]The American Thoracic Society.ATS statement:guidelines for the six-minute walk test.Am J Respir Crit Care Med,2002,166(1):111-117.
[13]Rector TS,Cohn JN.Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire:reliability and validity during a randomized,double-blind,placebo-controlling trial of pimobendan.Pimobendan Multicentre Research Group.Am Heart J,1992,12(4):1017-1025.
[14]Cooper KH.A mean of assessing maximal oxygen intake.Correlation between field and treadmill testing.JAMA,1968,203(3):201-204.
[15]中华心血管病杂志编辑委员会心血管药物对策专题组。心血管药物临床试验评价方法建议。中华心血管病杂志,1998,26(6):405-413。
[16]Task force for the diagnosis and treatment of chronic heart failure European society of cardiology Guidelines for the diagnosis and treatment of chronic heart failure.Eur Heart,2001,22(17):1527-1560.
[17]Schaufelberger M,Swedberg K.Is 6-minute walk test of value in congestive heart failure? Am Heart J,1998,136(3):371-372.
[18]Bittner V,Weiner DH,Yusuf S,et al.Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction.SOLVD Investigators.JAMA,1993,270(14):1702-1707.
[19]Tor T,Kubo S,Cohn J.Patients self-assessment of their congestive heart failure.Part2:content,reliability and validity of a new measure,the Minnesota Living with Heart Failure Questionnaire.Heart Failure,1987;3:198-209.
[20]Cowley A J,Wiens B L,Segal R,et al.Randomised comparison of Losartan vs Captopril on quality of life in elderly patient with symptomatic heart failure:the Losartan heart failure ELITE quality of life sub-study.Qual Life Res,2000,9(4):377-384.
[21]Morcillo C,Aguado O,Delas J,et al.Utility of the Minnesota Living With Heart Failure Questionnaire for assessng qulaity of life in heart failure patients.Rev Esp Cardiol,2007,60(10):1093-1096.
[22]Ulrich S,Speich R,Domenighetti G,et al.Bosentan therapy for chronic thromboembolic pulmonary hypertension,A national open label study assessing the effect of Bosentan on haemodynamics,exercise capacity,quality of life,safety and tolerability in patients with chronic thromboembolic pulmonary hypertension(BOCTEPH-Study).Swiss Med Wkly,2007,137(41-42):573-580.
[23]Cleland JG,Calvert MJ,Verboven Y,et al.Effects of cardiac resynchronization therapy on long-term quality of life:an analysis from the Cardiac Resynchronisation-Heart Failure(CARE-HF) study.Am Heart J,2009,157(3):457-466.
[24]Alla F,Briancon S,Guillemin F,et al.Self-rating of quality of life provides additional prognostic information in heart failure.Insights into the EPICAL study.Eur J Heart Fail,2002,4(3):337-343.
[25]Task force for the diagnosis and treatment of chronic heart failure of European society of cardiology.Guideline for the diagnosis and treatment of chronic heart failure.Eur Heart J,2001,22:1527-1560.
[26]汪林,朱文玲,陈连凤,等。心力衰竭患者治疗中的血浆氮末端-前体脑钠肽浓度。中华内科杂志,2005,44(3):177-179。
[27]Troughton RW,Frampton CM,Yandle TG,et al.Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide(NT-proBNP)concentration].Lancet,2000,355(9210):1126-1130.
[28]Miller WL,Hartman KA,Grill DE,et al.Only large reductions in concentrations of natriuretic peptides(BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure.Clin Chem,2009,55(1):78-84.
[29]Omland T,de lemos JA.Amino-terminal pro-B-type natriuretic peptides in stable and unstable ischemic heart diseases.Am J Cardiol,2008,101(3A):67-71.
[30]Schou M,Gustafsson F,Kistorp CN,et al.Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure.Am J Cardiol,2007,100(10):1571-1576.
[31]Morqenthaler NG,Struck J,Jochberqer S,et al.copeptin:clinical use of a new biomarker.Trends Endocrinol Metab,2008,19(2):43-49.
[32]Bhandari SS,Loke I,Davies JE,et al.Gender and renal function influence plasma levels of copeptin in healthy individuals.Clin Sci(Lond),2009,116(3):257-263.
[33]Fenske W,Stork S,Blechschmidt A,et al.Copeptin in the differential diagnosis of hyponatremia.J Clin Endocrinol Metab,2009,94(1):123-129.
[34]Neuhold S,Huelsmann M,Strunk G,et al.Comparison of copeptin,B-type natriuretic peptide,and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure:prediction of death at different stage of the disease.J Am Coll Cardiol,2008,52(4):266-272.
[35]Kelly D,Squire IB,Khan SQ,et al.C-terminal provasopressin(copeptin) is associated with left ventricular dysfunction,remodeling,and clinical heart failure in survivors of myocardial infarction.J Card Fail,2008,14(9):739-745.
[36]Stoiser B,Mortl D,Hulsmann M,et al.Copeptin,a fragment of the vasopressin precursor,as a novel predictor of outcome in heart failure.Eur J Clin Invest,2006,36(11):771-778.
[37]Geqenhuber A,Struck J,Dieeplinqer B,et al.Comparative evaluation of B-type natriuretic peptide,mid-regional pro-A-type natriuretic peptide,mid-regional pro-adrenomedullin,and Copeptin to predict 1-yeart mortality in patients with acute destabilized heart failure.J Card Fail,2007,13(1):42-49.
[38]Voors AA,von Haehling S,Anker SD,et al.C-terminal provasopressin (copeptin) is a strong prognostiv marker in patients with heart failure after an acute myocardial infarction:results from the OPTIMAAL study.Eur Heart J,2009 Apr 3,Epub ahead of print.
[39]Khan SQ,Dhillon OS,O'Brien RJ,et al.C-terminal provasopressin(copeptin)as a novel and prognostic marker in acute myocardial infarction:Leicester Acute Myocardial Infarction Peptide(LAMP) study.Circulation,2007,115(16):2103-2110.
[40]Cicoira M,Bolger AP,Doehner W,et al.High tumor necrosis factor-alpha levels are associated with exercise intolerance and neuro-hormonal activation in chronic heart failure patients.Cytokine,2001,15(2):80-86.
[41]Hsu CP,Huang CY,Wang JS,et al.Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.Ann Thorac Surg,2008,86(4):1243-1249.
[42]Westermann D,Riad A,Lettau O,et al.Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure.Hypertension,2008,52(6):1068-1075.
[43]周文武,林玲,陈军等。冠脉结扎法制作大鼠心肌缺血模型。中国实验动物学报,2004,12(4):226-229。
[44]徐叔云,卞如濂,陈修。药理实验方法学。第三版,北京:人民卫生出版社,2001:179。
[45]Miqrino RQ,Zhu X,Morker M,et al.Myocardial dysfunction in the periinfarct and remote regions following anterior infarction in rats quantified by 2D radial strain echocardiography:an observational cohort study.Cardiovasc Ultrasound,2008,29(6):17.
[46]黄国倩,刘虹,舒先红,等。超声心动图评价粒细胞集落刺激因子动员自身骨髓干细胞对心肌梗死后左心室重构及心功能的影响。中华超声影像学杂志,2004,13(11):848-852。
[47]Schwarz ER,Pollick C,Dow J,et al.A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res, 1998,39(1):216-223.
[48] Kanno S, Lemer DL, Schuessler RB, et al. Echocardiographic evaluation of ventricular remodeling in a mouse model of myocardial infarction. J Am Soc Echocardiogr, 2002,15(6):601 -609.
[49] Scherrer CM, Steudel W, Hunziker PR, et al. Three-dimensional echocardiographic assessment of left ventricular wall motion abnormalities in mouse myocardial infarction. J Am Soc Echocardiogr, 1999,12(10):834-840.
[50] Yaoita H, Sakabe A, Maehara K, et al. Different effects of carvedilol,metoprobol and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation, 2002,105(8):975-980.
[51] Brog KT, Caulfiele B. The collagen matrix of heart. Fed Proc, 1981,40(7):2037-2041.
[52] Weber KT, Eghbali M. Collagen and the myocardium: fibrilar structure,biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem, 1990, 96(1): 1-14.
[53] Juan W, Nakazawa M, Watanabe K, et al. Quinapril inhibits progress of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. Mol Cell Biochem, 2003,251(1-2):77-82.
[54] Umar S, Bax JJ, Klok M, et al. Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy. Eur J Heart Fail,2008,100(9):878-883.
[55] Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypetens,2007,9(7):546-550.
[56] Zhang P, Yang YJ, Chen X, et al. Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2005,27(1):53-61.
[57] Nishikawa N, Masuyama T, Yamamoto K, et al. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol, 2001,38(5):1539-1545.
[58] Matsumoto R, Yoshiyama M, Omura T, et al. Effects of aldosterone receptor antagonist and angiotensin type I receptor bolocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction. Circ J, 2004,68(4):376-382.
[59] Jirmar R, Pelouch V, Widimsky P, et al. Infuluence of primary coronary intervention on myocardial collagen metabolism and left ventricle remodeling predicted by collagen metabolism markers. Int Heart J, 2005,46(6):949-959.
[60] Angoulvant D, Fazel S, Weisel RD, et al. Cell-based gene therapy modifies matrix remodeling after a myocardial infarction in tissue inhibitor of matrix metalloproteinase-deficient mice. J Thorac Cardiovasc Surg, 2009,137(2):471-480.
[61] Cerisano G, Parodi G, Dovellini EV, et al. Time course of serum collagen types I and III metabolism products after reperfused acute myocardial infarction in patients with and without systemiv hypertension. J Hum Hypertens, 2009,23(1):40-47.
[62] Radovan J, Vaclav P, Petr W, et al. Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction. Mol Cell Biochem,2006,293(1-2):71-78.
[63] Wei S, Chow LT, Shum IO, et al. Left and right ventricular collagen type I/III ratios and remodeling post-myocardial infarction. J Card Fail, 1999,5(2):117-126.
[64] Gomes MC, Ferreira A, Bettencourt P. Physiopathology of heart failure. Rev Port Cardiol, 2004,23(2):117-123.
[65] Gheorghiade M, De Luca L, Bonow RO. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am J Cardiol, 2005,96(12A):3-9.
[66] Spinarova L, Spinar J, Vasku A, et al. Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients.Exp Mol Pathol, 2008,84(3):251-255.
[67] De Bold AJ, de Bold ML. Determinants or natriuretic peptide production by the heart: basic and clinical implications. J Investig Med, 2005,53(7):371-377.
[68] Barra S, Vitagliano A, Cuomo V, et al. Vascular and metabolic effects of angiotensin II receptor blockers. Expert Opin Pharmacother, 2009,10(2):173-189.
[69] 张婷,崔颖。心血管疾病治疗新靶点。中国新药杂志, 2001, 40(5): 338-340。
[70] Aranguix-Urroz P, Soto D, Contreras A, et al. Differential participation of angiotensin II type 1 and 2 receptors in the regulation of cardiac cell death triggered by angiotensin Ⅱ.Am J Hypertens,2009(Epub ahead of print).
[71]Krum H,Abraham WT.Heart failure.Lancet,2009,373(9667):941-955.
[72]Reddy HK,Campbell SE,Janicki JS,et al.Coronary microvascular fluid flux and permeability influence of angiotensin Ⅱ aldosterone and arterial hypertension.J Lab Clin Meal,1993,121(3):510-521.
[73]周玉杰,汪丽蕙,柯元南,等。碱性成纤维细胞生长因子对血管平滑肌细胞及内膜损伤后血管Ⅰ及Ⅲ型胶原mRNA表达的影响。中华心血管病杂志,1998,26(1):59-61。
[74]Crabos M,Roth M,Hahn AW,et al.Characterization of angiotensin Ⅱ receptors in cultured adult rat cardiac fibroblasts.J Clin Invest,1994,93(6):2372-2378.
[75]Brilla CG,Zhou G,Matsubara L,et al.Collagen metabolism in cultured adult rat cardiac fibroblasts:response to angiotensin Ⅱ and aldosterone.J Mol Cell Cardiol,1994,26(7):809-820.
[76]叶刚,陈尚恭,陈孟琴,等。心肌局部肾素-血管紧张素系统在心肌缺血及再灌注损伤时的激活及Losartan的保护作用。高血压杂志,1996,4(3):178-181。
[77]Lijnen PJ,Petrov VV.Role of intracardiac rennin-angiotensin-aldosterone syetem in extracellular matrix remodeling.Methods Find Exp Clin Pharmacol,2003,25(7):541-564.
[78]Gombos T,Forhecx Z,Pozsonyi Z,et al.Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure.Inflamm Res,2009(Epub ahead of print).
[79]Adlbrecht C,Hulsmann M,Strunk G,et al.Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure.Eur J Heart Fail,2009(Epub ahead of print).
[80]Schorlemmer A,Matter ML,Shohet RV.Cardioprotective signaling by endothelin.Trends Cardiovasc Med,2008,18(&):233-239.
[81]Bras Silva C,Leite Moreira AF.Myocardial effects of endothelin-1.Rev Port Cardiol,2008,27(7-8):925-951.
[82]Bras-Silva C,Leite-Moreira AF.Myocardial effects of endothelin-1.Rev Port Cardiol,2008,27(7-8):925-951.
[83]Lee CS,Tkacs NC.Current concepts of neurohormonal activation in heart failure:mediators and mechanisms.AACN Adv Crit Care,2008,19(4):364-385.
[84]Boldanoa T,Noveanu M,Breidthardt T,et al.Impact of history of heart failure on diagnostic and prognostic value of BNP:results from the B-type natriuretic peptide for acute shortness of breath evaluation(BASEL) study.Int J Cardiol,2009 Jan 28.[Epub ahead of print]
[85]Zuber M,Cuculi F,Jost CA,et al.Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure.Scand Cardiovasc J,2009,26:1-6.
[86]Sakata K,Iida K,Mochiduki N,et al.Brain natriuretic peptide(BNP) level is closely related to the extent of left ventricular sympathetic overactivity in chronic heart failure.2009,48(6):393-400.
[87]Novo G,Amoroso GR,Fazio G,et al.Biomarkers in heart failure.Front Biosci,2009,14:2484-2493.
[88]Lainscak M,von Haehling S,Anker SD.Natriuretic peptides and other biomarkers in chronic heart failure:from BNP,NT-proBNP and MR-proBNP to routine biochemical markers.Int J Cardiol,2009,132(3):303-311.
[89]Clerk A,Sugden PH.Inflame my heart(by p38-MAPK).Circ Res,2006,99(5):455-458.
[90]Liu YH,Wang D,Rhaleb NE,et al.Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction.J Card Fail,2005,11(1):74-81.
[91]Frantz S,Behr T,Hu K,et al.Role of p38 mitogen-activated protein kinase in cardiac remodeling.Br J Pharmacol,2007,150(2):130-135.
[92]杨丽霞,王先梅,石燕昆,等。细胞外信号调节激酶的变化在心力衰竭患者心肌重构中的意义。心脏杂志,2006,18(1):62-64。
[93]Bueno OF,De Windt LJ,Lim HW,et al.The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo.Circ Res,2001,88(1):88-96.
[94]Ueyama T,Kawashima S,Sakoda T,et al.Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.J Mol Cell Cardiol,2002,32(6):947-960.
[95]Liu J,Wu LL,Li L,et al.Growth promoting effect of platelet-derived growth factor on rat cardiac mycytes.Regul Pept,2005,127(1-3):11-18.
[96]Clerk A,Aggeli IK,Stathopoulou K,et al.Peptide growth factors signal differentially through protein kinase C to extracellular signal regulated kinases in neonatal cardiomyocytes.Cell Signal,2006,18(2):225-235.
[97]Das A,Xi L,Kukreja RC.Protein kinase G-dependent cardio-protective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta.J Biol Chem,2008,283(43):29572-29585.
[98]Baines CP,Molkentin JD.Stress signaling pathways that modulate cardiac myocyte apoptosis.J Mol Cell Cardiol,2005,38(1):47-62.
[99]Niizeki T,Takeishi Y,Arimoto T,et al.Cardiac specific over-expression of diacylglycerol kinase zeta attenuates left ventricular remodeling and improves survival after myocardial infarction.Am J Physiol Heart Circ Physiol,2007,292(2):1105-1112.
[100]Yasaka A,Hayashida W.Alterations of load-induced p38 MAP kinase activation in failing rat hearts.Biochem Biophys Res Commun,2001,285(2):503-507.
[101]Lymperopoulos A,Renqo G,Zincarelli C,et al.An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin Ⅱ-induced aldosterone production in vitro and in vivo.Proc Natl Acad Sci USA,2009,106(14):5825-5830.
[102]Boer RA,Pokharel S,Flesch M,et al.Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin Ⅱ driven progression towards overt heart failure in homozygous TGR(mRen2)27.J Mol Med,2004,82(10):678-687.
[103]Liang FQ,Lu S,Gardner DG,et al.Endothelin dependent and independent components of strain activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen activated protein kinase.Hypertension,2000,35(2):188-192.
[104]孙宁玲,王鸿懿,陈源源,等。ERK表达及活化在自发性高血压大鼠心肌肥厚中作用的研究。高血压杂志,2002,10(4):252。
[105]Aoki H,Richmond M,Tzumo S,et al.Specific role of the extracellular signal-regulated kinase pathway in angiotensin Ⅱ-induced cardiac hypertrophy in vitro.Biochem J,2000,347(1):275-284o
[106]王晋明,张庆华,王芳,等。厄贝沙坦和咪达普利对高血压大鼠心肌细胞外信号调节激酶的影响。中华心血管病杂志,2002,30(6):342-345。
[107]杨丽霞,王先梅,石燕昆,等。细胞外信号调节激酶的变化在心力衰竭患者心肌重构中的意义。心脏杂志,2006,18(1):62-64。
[108]Liang Q,Elson AC,Gerdes AM.p38 MAP kinase activity is correlated with angiotensin Ⅱ type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats. J Card Fail,2006,12(6): 479-486.
[109] Clerk A, Cullingford TE, Fuller SJ, et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol,2007,212(2):311-322.
[110] Hag S, Choukroun G, Lim H, et al. Differentia activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure.Circulation, 2001,103(5):670-677.
[111] Ng DC, Court NW, dos Remedios CG, et al. Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts. Cardiovasc Res, 2003,57(2):333-346.
[112] Freed DH, Borowiec AM, Angelovska T, et al. Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways. Cardiovasc Res, 2003,60(2):365-375.
[113]Takahashi K, Fukushima S, Yamahara K, et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart.2008,118(14):106-114.
[114] Frantz S, Behr T, Hu K, et al. Role of p38-MAPK inhibtors in the treatment of ischemic heart disease. Pharmacol Ther, 2007,116(2): 192-206.
[115] Liu YH, Wang D, Rhaleb NE, et al. Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. J Card Fail, 2005,11(1):74-81.
[116]Tenhunen O, Soini Y, lives M, et al. p38 kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms. Faseb J, 2006,20(11):1907-1909.
[117] See F, Thomas W, Way K, et al. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol, 2004,44(8): 1679-1689.
[118] Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibtors in the treatment of ischaemic heart disease. Pharmacol Ther, 2007,116(2): 192-206.
[119] Kyoi S, Otani H, Matsuhisa S, et al. Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc Res, 2006,69(4):888-898.
[1]Cooper KH.A means of assessing maximal oxygen intake.Correlation between field and treadmill testing.JAMA,1968,203(3):201-204.
[2]Lisboa BC,Barria PP,Yanez VJ,et al.Six minutes walk for the assessment of patients with chronic obstructive pulmonary disease.Rev Med Chil,2008,136(8):1056-1064.
[3]李娜,邱晨,魏永丽。六分钟步行实验与慢性阻塞性肺疾病患者肺功能的关系。中国组织工程研究与临床康复,2008,12(11):2116-2119。
[4]Jehn M,Schrnidt TA,Schuster T,et al.Daily walking performance as an independent predictor of advanced heart failure:prediction of exercise capacity in chronic heart failure.Am Heart J,2009,157(2):292-298.
[5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会。慢性心力衰竭诊断治疗指南。中华心血管病杂志,2007,35(12):1076-1093。
[6]中华心血管病杂志编辑委员会心血管药物对策专题组。心血管药物临床试验评价方法建议。中华心血管病杂志,1998,26(6):405-413。
[7]Boxer RS,Wang Z,Walsh SJ,et al.The utility of the 6-minute walk test as a measure of frailty in older adults with heart failure.Am J Geriatr Cardiol,2008,17(1):7-12.
[8]Task force for the diagnosis and treatment of chronic heart failure European society of cardiology Guidelines for the diagnosis and treatment of chronic heart failure.Eur Heart,2001,22(17):1527-1560.
[9]Foley PW,Stegemann B,Smith RE,et al.Cardiac resynchronization therapy in patients with mildly impaired left ventricular function.Pacing Clin Electrophysiol,2009,Suppl1:S186-189.
[10]Raymond Lee,Yiong HC,Jennifer W,et al.The 6-minute walk test predicts clinical outcome in Asian patients with chronic congestive heart failure on contemporary medical therapy:a study of the multiracial population in Singapore.International Cardio,2007,119(2):168-175.
[11]Guyatt GH,Sullivan MJ,Thompson PJ,et al.The 6-minute walk:a new measure of exercise capacity in patients with congestive heart failure.Can Med Assoc,1985,32(8):919-923.
[12]Bittner V,Weiner DH,Yusuf S,et al.Prediction of mortality and morbidity with a 6-minute test in patients with left ventricular dysfunction.SOLVD Ivestigators.JAMA,1993,270(14):1702-1707.
[13]陈协兴,洪华山,陈良龙,等。慢性心力衰竭患者6min步行距离与血清脑钠肽水平的临床研究。中国临床药理学与治疗学,2004,9(5):561-564。
[14]慧海鹏,许顶立,李琦,等。六分钟步行对充血性心力衰竭患者QT离散度的影响。中国现代医学杂志,2002,12(16):47-48。
[15]The American Thoracic Society.ATS statement:guidelines for the six-minute walk test.Am J Respir Crit Care Med,2002,166(1):111-117.
[16]王惠兰,刘乾惠,李雪红。鼓励因素对心力衰竭患者六分钟步行实验的影响。中国临床康复,2004,8(30):6550-6551。
[17]Laterence P,Cahalin MA,Michael A,et al.The six minutes walk test predicts peak oxygen uptake and survival in patients with advanced heart failure.Chest,1996,110(3):325-332.
[18]Opasich C,Pinna GD,Mazza A,et al.Reproducibility of the six-minute walking test in patients with congestive heart failure:practical implications.Am J Cardiol,1998,81(12):1497-500.
[19]Demers C,Mckelvie RS,Negassa A,et al.Reliability,validity and responsiveness of the six-minute walk test in patients with heart failure.Am Heart J,2001,142(4):698-703.
[20]蒙涛,曹加淮,李江津,等。慢性心力衰竭患者运动训练的临床意义。中国现代药物应用,2008,2(1):43-44。
[21]Zugck C,Kruger C,Durr S,et al.Is the 6-minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J,2000,21(7):540-549.
[22]冷秀玉,曾武涛,陈国伟等。6分钟步行实验与慢性心力衰竭。中国心血管杂志,2003,8(6):412-413。
[23]Arslan S,Erol MK,Gundoqdu F,et al.Prognostiv value of 6-minute walk test in stable outpatients with heart failure.Tex Heart Inst J,2007,34(2):166-169.
[24]Cahalin LP,Mathier MA,Semigran MJ,et al.The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure.Chest,1996,110(2):325-332.
[25]Peeters P,Mets T.The 6-minute walk as appropriate exercise test in elderly patients with chronic heart failure.Gerontol A Biol Sci,1996,51(4):147-151.
[26]Chien CL,Lee CM,Wu YW,et al.Home-based exercise increases exercise capacity but not quality of life in people with chronic heart failure:a systematic review.Aust J physiother,2008,54(2):87-93.
[27]Haass M,Zuqck C,Kubler W.The 6 minute walking test:a cost-effective alternative to spiro-ergometry in patients with chronic heart failure? Z Kardiol,2000,89(2):72-80.
[28]Alahdab MT,Mansour IN,Napan S,et al.Six minute walk test predicts long-term all-cause mortality and heart failure rehospitalization in African-American patients hospitalized with acute decompensated heart failure.2009,15(2):130-135.
[29]Zuqck C,Kruqer C,Durr S,et al.Is the 6 minute walk test a reliable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? Eur Heart J,2000,21(7):507-508.
[30]Shah MR,Hasselblad V,Gheorghiade M,et al.Prognostic usefulness of six-minute walk in patients with advanced congestive heart failure secondary to ischemic of non-ischemic cardiomyopathy.Am J Cardiol,2001,88(9):987-993.
[31]Roul G,Germain P,Bareiss P,et al.Does the 6-minute walk test predict the prognosis in patients with NYHA class Ⅱ or Ⅲ chronic heart failure? Am Heart J,1998,136(3):449-457.
[32]Frankenstein L,Zuqck C,Nelles M,et al.Sex-specific predictive of 6-minute walk test in chronic heart failure is not enhanced using percent achieved of published reference equations.J Heart Lung Transplant,2008,27(4):427-434.
[33]Zhou SP,Yang CM,Shi WB,et al.Study on six-minute walk test and cardiac output response against exercise in patients with chornic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi, 2008,36(3):236-239.
[34]Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces does related improvements in left ventricular function an survival in subjects with chronic heart failure. Circulation, 1996,94( 11 ):2807-2816.
[35]Gualeni A, Aloia AD, Gentiliui A, et al. Effects of maximally tolerated oral therapy on the six-minute walking test in patients with chronic congestive heart failure secondary to either ischemic or idiopathic dialated cardiomyopathy. Am J Cardiol, 1998,81(11): 1370-1372.
[36]Kum LC, Yip GW, Lee PW, et al. Comparison of angiotensin-converting enzyme inhibitor along and in combination with irbesartan for the treatment of heart failure. Int J Cardiol, 2008,125(1): 16-21.
[37]Sisakian H, Torqomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischemic cardiomyopathy. Acta Cardiol, 2007,62(5):493-499.
[38]Chwyczko T, Sterlinski M, Maciaq A, et al. Impact of cardiac resynchronization the therapy on adaption of circulatory and respiratory systems to exercise assessed by cardiopulmonary exercise test in patients with chronic heart failure.Kardiol Pol, 2008,66(4):406-414.
[39] Sterlinski M, Maciaq A, Kowalski 0, et al. Mortality in patients with heart failure treated with cardiac resynchronization therapy. A long-term multi-centre follow-up study. Kardiol Pol, 2007,65(11):1287-93.
[40]Foley PW, Steqemann B, Smith RE, et al. Cardiac resynchronization therapy in patients with mildly impaired left ventricular function. Pacing Clin Electrophysiol,2009,32 Supp11:S186-189.
[41]Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol, 2008,52(15):1239-1246.
[42]Macias A, Gavira JJ, Castano S, et al. Left ventricularu pacing site in cardiac resynchronization therapy: clinical follow-up and predictors of failed lateral implant. Eur J Heart Fail, 2008,10(4):421-427.
[43]Foray A, Williams D, Reemtsma K, et al. Assessment of sub-maximal exercise capacity in patients with left ventricular assist devices. Circulation, 1996,94(9 suppl):II 222-226.
[44]Auricchio A,Stellbrink C,Sack S,et al.The pacing therapies for congestive heart failure(PATH-CHF) study:rationale,design,and endpoints of a prospective randomized multicentre study.Am J Cardiol,1999,83(5B):130D-135D.
[45]Hoijer CJ,Meurling C,Brandt J.Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure:a double-blind,randomized crossover study.Europace,2006,8(1):51-55.
[46]Jaski BE,Jessup ML,Mancini DM,et al.Calcium upregulation by percutaneous administration of genen therapy in cardiac disease(CUPID Trial),a first-in-human phase 1/2 clinical trial.J Card Fail,2009,15(3):171-181.
[47]Meyer K,Schwaibold M,Westbrook S,et al.Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure.Am Heart J,1997,133(4):447-453.
[48]Piepoli MF,Capucci A.Exercise training in heart failure:effect on morbidity and mortality.Int J Cardiol,2000,73(1):3-6.
[49]Jankowska EA,Weqrzynowska K,Superlak M,et al.The 12-week progressive quadriceps resistance training improves muscle strength,exercise capacity and quality of life in patients with stable chronic heart failure.Int J Cardiol,2008,130(1):36-43.
[50]Dracup K,Evangelista LS,Hamilton MA,et al.Effects of a home-based exercise program on clinical outcomes in heart failure.Am Heart J,2007,154(5):877-883.
[51]许顶立,慧海鹏,侯玉清,等。步行运动对充血性心力衰竭患者血浆可溶性炎性细胞因子和氧化应激的影响。中华心血管病杂志,2001,29(7):406-409。
[52]慧海鹏,许顶立,侯玉清,等。充血性心力衰竭患者运动前后血浆细胞间黏附分子-1含量及临床意义。岭南心血管病杂志,2001,7(6):415-417。
[53]王艳,刘应才,张泽芳,等。6分钟步行实验对心力衰竭患者白细胞介素10和肿瘤坏死因子α水平的影响。中国煤炭工业医学杂志,2004,7(5):394-395。
[54]王兵,许顶立,侯玉清,等。六分钟步行运动训练对慢性心力衰竭患者血浆肾素和血管紧张素Ⅰ的影响。中国循环杂志,2002,17(4):266-268。
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会。慢性心力衰竭诊断治疗指南。中华心血管病杂志,2007,35(12):1076-1093。
[2]Rich MW.Heart failure in older adults.Med Clin North Am,2006,90(5):863-885.
[3]Chandrashekhar Y.Role of apoptosis in ventricular remodeling.Curr Heart Fail Rep,2005,2(1):18-22.
[4]Ibe W,Saraste A,Lindemann S,et al.Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodeling in dilated cardiomyopathy,but is not affected by growth hormone treatment.Eur J Heart Fail,2007,9(2):160-167.
[5]Okada H,Takemura G,Kosai K,et al.Combined therapy with cardio-protective cytokine administration and anti-apoptotic gene transfer in post-infarction heart failure.Am J Physiol Heart Circ Physiol,2009,296(3):H616-626.
[6]Wang GY,Bergman MR,Nguyen AP,et al.Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility.Cardiovasc Res,2006,69(3):688-696.
[7]Lakkis J,Lu WX,Weir MR.RAAS escape:a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep,2003,5(5):408-417.
[8] Zhang X, Yang YJ, Zhu WL, et al. Effects of angiotensin II receptor antagonism on matrix metalloproteinases and fibronectin in rats with experimental myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi, 2006,34(11):1029-1034.
[9] Gonzalez A, Lopez B, Diez J. Fibrosis in hypertensive heart disease: role of the rennin-angiotensin-aldosterone system. Med Clin North Am, 2004,88(1):83-97.
[10] Schroder D, Heger J, Piper HM, et al. Angiotensin II stimulates apoptosis via TGF-betal signaling in ventricular cardiomyocytes. J Mol Med, 2006,84(11):975-983.
[11] Yee DK, Suzuki A, Luo L, et al. Identification of structural determinants for G protein-independent activation of mitogen-activated protein kinases in the seventh trans-membrane domain of the angiotensin II type 1 receptor. Mol Endocrinol, 2006,20(8): 1924-1934.
[12]Paradis P, Dali YN, Paradis FW, et al. Over-expression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proe Natl Acad Sci USA, 2000,97(2):931-936.
[13]Rittenhouse SK. Spironolactone for heart failure: a worthy addition to therapy.Adv Nurse Prac, 2001,9(1):34-36.
[14] Martinez Reding J. Heart failure, neurohormonal treatment. Arch Cardiol Mex,2007,77(4): 106-110.
[15] Mulder P, Mellin V, Favre J, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J, 2008 Jun 27. [Epub ahead of print]
[16]Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol, 2001,37(5):1228-1233.
[17] Berry C, Murphy NF, De Vito G, et al. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail,2007,9(4):429-434.
[18]Xu G, Liu A, Liu X. Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules.Nephrology(Carlton),2008,13(8):694-701.
[19]Nishiyama A,Abe Y.Molecular mechanisms and therapeutic strategies of chronic renal injury:renoprotective effects of aldosterone blockade.J Pharmacol Sci,2006,100(1):9-16.
[20]Dash R,Schmidt AG,Pathak A,et al.Differential regulation of p38mitogen-activated protein kinase mediates gender-dependent catecholamine -induced hypertrophy.Cardiovasc Res,2003,57(3):704-714.
[21]曾欣,张元春。心脏胶原纤维增生及其影响因素。心血管病学进展,2003,24(4):303-306。
[22]Hamid T,Gu Y,Ortines RV,et al.Divergent tumor necrosis factor receptor-related remodeling response in heart failure:role of nuclear factor-kappaB and inflammatory activation.Circulation,2009,119(10):1386-1397.
[23]Mann DL.Recent insights into the role of tumor necrosis factor in the failing heart.Heart Fail Rev,2001,6(2):71-80.
[24]El AD,Zimlichman R,Mashiach Y,et al.Adenosine and TNF-alpha exert similar inotropic effect on heart cultures,suggesting a cardioprotective mechanism against hypoxia.Life Sci,2007,81(10):803-813.
[25]Sun M,Chen M,Dawood F,et al.Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.Circulation,2007,115(11):1398-1407.
[26]Wang M,Tsai BM,Crisostomo PR,et al.Tumor necrosis factor receptor 1signaling resistance in the female myocardium during ischemia.Circulation,2006,114(1):1282-1289.
[27]Yang LL,Gros R,Kabir MG,et al.Conditional cardiac over-expression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice.Circulation,2004,109(2):255-261.
[28]Schula R,Heusch G.Tumor necrosis factor-alpha and its receptors 1 and 2:Yin and Yang in myocardial infarction? Circulation,2009,119(10):1355-1357.
[29]Pagani FD,Baker LS,His C,et al.Left ventricular systolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.J Clin Invest,1992,90(2):389-392.
[30]Sun M,Chen M,Dawood F,et al.Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.Circulation,2007,115(11):1398-1407.
[31]Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation,1997,95(5):1247-1252.
[32]Flesch M, Hoper A, Delltalia L, et al. Activation and functional significance of the rennin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation, 2003,108(5):598-604.
[33]Berry MF, Woo YJ, Pirolli TJ, et al. Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J Hert Lung Transplant, 2004,23(9):1061-1068.
[34] Sihvola RK, Koskinen PK, Pulkkinen VP, et al. Inhibition of tumor necrosis factor-alpha attenuates myocardial remodeling in rat cardiac allografts. J Heart Lung Transplant, 2006,25(5):569-578.
[35]Mlyauchi T. Endothelin and heart failure. Nippon Rinsho, 2004,62(9): 648-654.
[36] Rivera M, Cortes R, Portoles M, et al. Plasma concentration of big endthelin-1 and its relation with plasma NT-proBNP and venteicular function in heat failure patients. Rev Esp Cardiol, 2005,58(3):278-284.
[37]Konstam MA, DeNofrio D. Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development. Circulation,2004,109(2):143-145.
[38]Stessel H, Brunner F. Effect of endothelin antagonism on contractility,intracellular calcium regulation and calcium regulatory protein expression in right ventricular hypertrophy of the rat. Basic Clin Pharmacol Toxicol, 2004,94(1):37-45.
[39]Oie E, Clausen OP, Yndestad A, et al. Endothelin receptor antagonism attenuates cardiomyocyte apoptosis after induction of ischemia rats. Scand Cardiovasc J,2002,36(2):108-116.
[40]Ito H, Hirata Y, Adachi S, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II induced hypertrophy in cultured rat cardiomyocytes. J Clin Ivest, 1993,92(1):398-403.
[41]Jolda MB, Salomon P. Cytokines and remodeling of the heart in patients with congestive heart failure. Pol Arch Med Wewn, 2003,109(1):23-33.
[42]Boglioni FV, Metra M, Locati M, et al. Role of inflammation mediators in the pathogenesis of heart failure. Ital Heart J Suppl, 2001,2(6)628-633.
[43]Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation, 2008,117(20):2670-2683.
[44]Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol,1999,83(1): 376-382.
[45]Pennica D, Shaw KJ, Swanson TA, et al. Cardiotrophin-1, Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J Biol Chem, 1995,270(18):10915-10922.
[46]Kunisada K, Hirota H, Fujio Y, et al. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation,1996,94(3):2626-2632.
[47]Feuerstein GZ, Bril A, Rufflo RR, et al. Protective effects of carvedilol in the myocardium. Am J Cardiol, 1999,83(2):376-380.
[48]Qanud K, Mamdani M, Pepe M, et al. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure. Am J Physiol Heart Circ Physiol,2008,295(5):2098-2105.
[49]Radovanovix S, Krotin M, Simic DV, et al. Markers of oxidative damage in chronic heart failure: role in disease progression. Redox Rep, 2008,13(3):109-116.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |